✓ Produto localizado
Medicamentos E Saúde
Medicamentos E Saúde
PUREGON PEN 300UI X 1CARP 0 6 AGU
Puregon- GTIN / EAN
- 7897572002456
- NCM
- 30049099
- CEST
- Não informado
- Conteúdo
- Não informado
Dados de produto preservados no idioma original.
PUREGON PEN 300UI X 1CARP 0 6 AGU é fabricado pela Puregon, na categoria Medicamentos E Saúde, com código de barras 7897572002456. Classificado no NCM 30049099 (Outros).
Fonte: SI5 Global · código registrado em Brasil
Preço nos últimos 30 dias: R$ 916,15 em 1 loja
Classificação fiscal
- NCM
- 30049099Outros
Ficha técnica
- Medicamento
- True
- MarcaPropria
- Não
- NumeroRegistroMS
- 1.0171.0081.016-0
- NomeSubstanciaPrincipioAtivo
- Betafolitropina
- DescricaoBula
- %0A%09%09%09%09%09%09%3Ch2%3ELaborat%26%23xF3%3Brio%3C%2Fh2%3E%0A%3Cp%3Eorganon%3C%2Fp%3E%0A%3Ch2%3E%20Apresenta%26%23xE7%3B%26%23xE3%3Bo%20PUREGON%20%3C%2Fh2%3E%0A%3Cp%3ESolu%26%23xE7%3B%26%23xE3%3Bo%20injet%26%23xE1%3Bvel.%20Embalagem%20com%3A%3Cbr%3E%20-uma%20dose%20de%20300%20UI%20de%20betafolitropina%20%2B%206%20agulhas%20para%20inje%26%23xE7%3B%26%23xE3%3Bo.%3Cbr%3E%20-uma%20dose%20de%20600%20UI%20de%20betafolitropina%20%2B%206%20agulhas%20para%20inje%26%23xE7%3B%26%23xE3%3Bo.%3Cbr%3E%20A%20solu%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE9%3B%20acondicionada%20em%20carpules%20a%20serem%20utilizadas%20com%20uma%20caneta%20injetora%20PUREGON%20PEN%26%23xAE%3B.%3Cbr%3E%3C%2Fp%3E%0A%3Ch2%3E%20PUREGON%20%26%23x2013%3B%20Indica%26%23xE7%3B%26%23xF5%3Bes%20%3C%2Fh2%3E%0A%3Cp%3EEm%20mulheres%3Cbr%3E%20PUREGON%26%23xAE%3B%20%26%23xE9%3B%20indicado%20para%20o%20tratamento%20da%20infertilidade%20feminina%20nas%20seguintes%20situa%26%23xE7%3B%26%23xF5%3Bes%20cl%26%23xED%3Bnicas%3A%3Cbr%3E%20%26%23x2212%3BAnovula%26%23xE7%3B%26%23xE3%3Bo%20(incluindo%20s%26%23xED%3Bndrome%20de%20ov%26%23xE1%3Brios%20polic%26%23xED%3Bsticos)%20em%20mulheres%20que%20se%20mostraram%20n%26%23xE3%3Bo%20responsivas%20ao%20tratamento%20com%20citrato%20de%20clomifeno.%3Cbr%3E%20%26%23x2212%3BHiperestimula%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20controlada%20para%20induzir%20o%20desenvolvimento%20de%20m%26%23xFA%3Bltiplos%20fol%26%23xED%3Bculos%20em%20programas%20de%20reprodu%26%23xE7%3B%26%23xE3%3Bo%20assistida%20%5Bpor%20exemplo%2C%20fertiliza%26%23xE7%3B%26%23xE3%3Bo%20in%20vitro%2Ftransfer%26%23xEA%3Bncia%20de%20embri%26%23xF5%3Bes%20(FIV%2FTE)%2C%20transfer%26%23xEA%3Bncia%20intratub%26%23xE1%3Bria%20de%20gametas%20(GIFT)%20e%20inje%26%23xE7%3B%26%23xE3%3Bo%20intracitoplasm%26%23xE1%3Btica%20de%20espermatoz%26%23xF3%3Bide%20(ICSI)%5D.%3Cbr%3E%20%3Cbr%3E%20Em%20homens%3Cbr%3E%20%26%23x2212%3BEspermatog%26%23xEA%3Bnese%20deficiente%20devido%20ao%20hipogonadismo%20hipogonadotr%26%23xF3%3Bfico.%3Cbr%3E%3C%2Fp%3E%0A%3Ch2%3E%20Contra%20indica%26%23xE7%3B%26%23xF5%3Bes%20de%20PUREGON%20%3C%2Fh2%3E%0A%3Cp%3EEste%20medicamento%20%26%23xE9%3B%20contraindicado%20para%20uso%20por%20pessoas%20com%3A%3Cbr%3E%20Em%20mulheres%20e%20homens%3A%3Cbr%3E%20-Hipersensibilidade%20%26%23xE0%3B%20subst%26%23xE2%3Bncia%20ativa%20ou%20a%20quaisquer%20dos%20excipientes.%3Cbr%3E%20-Tumores%20de%20ov%26%23xE1%3Brio%2C%20mama%2C%20%26%23xFA%3Btero%2C%20test%26%23xED%3Bculos%2C%20hip%26%23xF3%3Bfise%20ou%20hipot%26%23xE1%3Blamo.%3Cbr%3E%20-Insufici%26%23xEA%3Bncia%20gonadal%20prim%26%23xE1%3Bria.%3Cbr%3E%20Adicionalmente%20para%20mulheres%3A%3Cbr%3E%20-Sangramento%20vaginal%20de%20causa%20indeterminada.%3Cbr%3E%20-Cistos%20ovarianos%20ou%20ov%26%23xE1%3Brios%20aumentados%2C%20n%26%23xE3%3Bo%20relacionados%20com%20s%26%23xED%3Bndrome%20de%20ov%26%23xE1%3Brios%20polic%26%23xED%3Bsticos.%3Cbr%3E%20-Malforma%26%23xE7%3B%26%23xF5%3Bes%20dos%20%26%23xF3%3Brg%26%23xE3%3Bos%20reprodutivos%20incompat%26%23xED%3Bveis%20com%20a%20gravidez.%3Cbr%3E%20-Miomas%20uterinos%20incompat%26%23xED%3Bveis%20com%20a%20gravidez.%3Cbr%3E%20%3Cbr%3E%20Este%20medicamento%20%26%23xE9%3B%20contraindicado%20para%20uso%20por%20mulheres%20gr%26%23xE1%3Bvidas%20ou%20que%20suspeitam%20que%20possam%20estar.%3Cbr%3E%3C%2Fp%3E%0A%20%20%20%20%20%20%20%20%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Famp-ad%3E%0A%3Ch2%3EAdvert%26%23xEA%3Bncias%3C%2Fh2%3E%0A%3Cp%3E-PUREGON%26%23xAE%3B%20pode%20conter%20tra%26%23xE7%3Bos%20de%20estreptomicina%20e%2Fou%20neomicina.%20Esses%20antibi%26%23xF3%3Bticos%20podem%20causar%20rea%26%23xE7%3B%26%23xF5%3Bes%20de%20hipersensibilidade%20em%20indiv%26%23xED%3Bduos%20sens%26%23xED%3Bveis.%3Cbr%3E%20-Antes%20de%20iniciar%20o%20tratamento%2C%20a%20infertilidade%20do%20casal%20deve%20ser%20avaliada%20conforme%20o%20caso.%20Em%20especial%2C%20os%20pacientes%20devem%20ser%20avaliados%20para%20hipotireoidismo%2C%20insufici%26%23xEA%3Bncia%20adrenocortical%2C%20hiperprolactinemia%20e%20tumores%20de%20hip%26%23xF3%3Bfise%20ou%20hipot%26%23xE1%3Blamo%20e%20deve%20ser%3Cbr%3E%20oferecido%20tratamento%20espec%26%23xED%3Bfico%20apropriado.%3Cbr%3E%20Em%20mulheres%3A%3Cbr%3E%20-S%26%23xED%3Bndrome%20de%20Hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20Ovariana%20(SHEO)%20%26%23xE9%3B%20uma%20situa%26%23xE7%3B%26%23xE3%3Bo%20cl%26%23xED%3Bnica%20distinta%20do%20aumento%20ovariano%20descomplicado.%20Os%20sinais%20e%20sintomas%20cl%26%23xED%3Bnicos%20da%20SHEO%20de%20leve%20a%20moderada%20s%26%23xE3%3Bo%20dor%20abdominal%2C%20n%26%23xE1%3Buseas%2C%20diarreia%20e%20aumento%20de%20leve%20a%20moderado%20dos%20ov%26%23xE1%3Brios%20e%20cistos%20ovarianos.%20SHEO%20grave%20pode%20representar%20risco%20%26%23xE0%3B%20vida.%20Sinais%20e%20sintomas%20cl%26%23xED%3Bnicos%20de%20SHEO%20grave%20s%26%23xE3%3Bo%20cistos%20ovarianos%20grandes%2C%20dor%20abdominal%20aguda%2C%20ascite%2C%20derrame%20pleural%2C%20hidrot%26%23xF3%3Brax%2C%20dispneia%2C%20olig%26%23xFA%3Bria%2C%20anormalidades%20hematol%26%23xF3%3Bgicas%20e%20ganho%20de%20peso.%20Em%20raras%20situa%26%23xE7%3B%26%23xF5%3Bes%2C%20pode%20ocorrer%20tromboembolismo%20venoso%20ou%20arterial%20em%20associa%26%23xE7%3B%26%23xE3%3Bo%20com%20a%20SHEO.%20Anormalidades%20transit%26%23xF3%3Brias%20nos%20testes%20de%20fun%26%23xE7%3B%26%23xE3%3Bo%20hep%26%23xE1%3Btica%20sugestivas%20de%20disfun%26%23xE7%3B%26%23xE3%3Bo%20hep%26%23xE1%3Btica%2C%20com%20ou%20sem%20altera%26%23xE7%3B%26%23xF5%3Bes%20morfol%26%23xF3%3Bgicas%20na%20bi%26%23xF3%3Bpsia%20hep%26%23xE1%3Btica%2C%20foram%20relatadas%20em%20associa%26%23xE7%3B%26%23xE3%3Bo%20com%20SHEO.%3Cbr%3E%20SHEO%20pode%20ser%20causada%20pela%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20gonadotropina%20cori%26%23xF4%3Bnica%20humana%20(hCG)%20e%20por%20gravidez%20(hCG%20end%26%23xF3%3Bgeno).%20SHEO%20precoce%20geralmente%20ocorre%20dentro%20de%20dez%20dias%20ap%26%23xF3%3Bs%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20hCG%20e%20pode%20estar%20associada%20com%20uma%20resposta%20excessiva%20ovariana%20a%20estimula%26%23xE7%3B%26%23xE3%3Bo%20de%20gonadotropina.%20SHEO%20tardia%20ocorre%20depois%20de%2010%20dias%20ap%26%23xF3%3Bs%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20hCG%2C%20como%20uma%20consequ%26%23xEA%3Bncia%20da%20altera%26%23xE7%3B%26%23xE3%3Bo%20hormonal%20por%20gravidez.%20Devido%20ao%20risco%20de%20desenvolvimento%20de%20SHEO%2C%20as%20pacientes%20devem%20ser%20monitoradas%20por%2C%20pelo%20menos%2C%20duas%20semanas%20ap%26%23xF3%3Bs%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20hCG.%3Cbr%3E%20Mulheres%20com%20fatores%20de%20risco%20conhecidos%20para%20uma%20resposta%20ovariana%20alta%20podem%20ser%2C%20especialmente%2C%20tendenciosas%20a%20desenvolver%20SHEO%20durante%20ou%20ap%26%23xF3%3Bs%20o%20tratamento%20com%20PUREGON%26%23xAE%3B.%20Para%20mulheres%20em%20seu%20primeiro%20ciclo%20de%20estimula%26%23xE7%3B%26%23xE3%3Bo%20ovariana%2C%20para%20as%20quais%20os%20fatores%20de%20risco%20s%26%23xE3%3Bo%20apenas%20parcialmente%20conhecidos%2C%20%26%23xE9%3B%20recomendada%20observa%26%23xE7%3B%26%23xE3%3Bo%20rigorosa%20para%20sinais%20e%20sintomas%20precoces%20da%20SHEO.%3Cbr%3E%20Para%20reduzir%20o%20risco%20de%20SHEO%20deve%20ser%20realizada%20avalia%26%23xE7%3B%26%23xE3%3Bo%20ultrassonogr%26%23xE1%3Bfica%20de%20desenvolvimento%20folicular%20antes%20do%20tratamento%20e%20em%20intervalos%20regulares%20durante%20o%20tratamento.%20A%20determina%26%23xE7%3B%26%23xE3%3Bo%20simult%26%23xE2%3Bnea%20das%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20de%20estradiol%20tamb%26%23xE9%3Bm%20pode%20ser%20%26%23xFA%3Btil.%20Em%20T%26%23xE9%3Bcnica%20de%20Reprodu%26%23xE7%3B%26%23xE3%3Bo%20Assistida%20(TRA)%20h%26%23xE1%3B%20um%20aumento%20do%20risco%20de%20SHEO%20com%2018%20ou%20mais%20fol%26%23xED%3Bculos%20de%2011%20mm%20de%20di%26%23xE2%3Bmetro%20ou%20maior.%20Quando%20houver%2030%20ou%20mais%20fol%26%23xED%3Bculos%20no%20total%2C%20%26%23xE9%3B%20recomendado%20suspender%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20hCG.%3Cbr%3E%20Dependendo%20da%20resposta%20ovariana%2C%20as%20seguintes%20medidas%20devem%20ser%20consideradas%20para%20reduzir%20o%20risco%20de%20SHEO%3A%3Cbr%3E%20-conter%20a%20estimula%26%23xE7%3B%26%23xE3%3Bo%20futura%20com%20gonadotropina%2C%20no%20m%26%23xE1%3Bximo%2C%20por%20tr%26%23xEA%3Bs%20dias%20(coasting)%3B%3Cbr%3E%20-suspender%20hCG%20e%20cancelar%20o%20ciclo%20de%20tratamento%3B%3Cbr%3E%20-administrar%20uma%20dose%20menor%20que%2010.000%20UI%20de%20hCG%20urin%26%23xE1%3Brio%20para%20o%20acionamento%20da%20fase%20final%20de%20matura%26%23xE7%3B%26%23xE3%3Bo%20do%20o%26%23xF3%3Bcito%2C%20por%20exemplo%2C%205.000%20UI%20de%20hCG%20urin%26%23xE1%3Brio%20ou%20250%20mcg%20de%20hCG%20recombinante%20(que%20%26%23xE9%3B%20equivalente%20a%20aproximadamente%206.500%20UI%20de%20hCG%3Cbr%3E%20urin%26%23xE1%3Brio)%3B%3Cbr%3E%20-cancelar%20a%20transfer%26%23xEA%3Bncia%20de%20embri%26%23xE3%3Bo%20fresco%20e%20criopreservar%20embri%26%23xF5%3Bes%3B%3Cbr%3E%20-evitar%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20hCG%20para%20suporte%20da%20fase%20l%26%23xFA%3Btea.%3Cbr%3E%20Se%20desenvolver%20SHEO%2C%20um%20gerenciamento%20padr%26%23xE3%3Bo%20e%20apropriado%20da%20SHEO%20deve%20ser%20implementado%20e%20seguido.%3Cbr%3E%20-Tor%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20tem%20sido%20relatada%20ap%26%23xF3%3Bs%20o%20tratamento%20com%20gonadotropinas%2C%20incluindo%20PUREGON%26%23xAE%3B.%20Tor%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20pode%20estar%20associada%20com%20outros%20fatores%20de%20risco%20tais%20como%20SHEO%2C%20gravidez%2C%20cirurgia%20abdominal%20anterior%2C%20hist%26%23xF3%3Brico%20de%20tor%26%23xE7%3B%26%23xE3%3Bo%20ovariana%2C%20cisto%20ovariano%20anterior%20ou%20atual%20e%20ov%26%23xE1%3Brios%20polic%26%23xED%3Bsticos.%20Dano%20ao%20ov%26%23xE1%3Brio%20devido%20ao%20reduzido%20suprimento%20sangu%26%23xED%3Bneo%20pode%20ser%20limitado%20pelo%20diagn%26%23xF3%3Bstico%20precoce%20e%20distor%26%23xE7%3B%26%23xE3%3Bo%20imediata.%3Cbr%3E%20-Eventos%20tromboemb%26%23xF3%3Blicos%2C%20separado%20e%20em%20associa%26%23xE7%3B%26%23xE3%3Bo%20com%20SHEO%2C%20foram%20relatados%20ap%26%23xF3%3Bs%20tratamento%20com%20gonadotropinas%2C%20incluindo%20PUREGON%26%23xAE%3B.%20Trombose%20intravascular%2C%20que%20pode%20ser%20origin%26%23xE1%3Bria%20de%20vasos%20arteriais%20ou%20venosos%2C%20pode%20resultar%20na%20redu%26%23xE7%3B%26%23xE3%3Bo%20do%20fluxo%20sangu%26%23xED%3Bneo%20para%20%26%23xF3%3Brg%26%23xE3%3Bos%20vitais%20ou%20extremidades.%20Em%20mulheres%20que%20apresentam%20fatores%20de%20risco%20para%20eventos%20tromboemb%26%23xF3%3Blicos%2C%20tais%20como%20antecedentes%20pessoais%20ou%20familiares%2C%20obesidade%20grave%20ou%20trombofilia%2C%20o%20tratamento%20com%20gonadotropinas%2C%20incluindo%20PUREGON%26%23xAE%3B%2C%20pode%20aumentar%20ainda%20mais%20esse%20risco.%20Nessas%20mulheres%2C%20o%20benef%26%23xED%3Bcio%20da%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20gonadotropina%2C%20incluindo%20PUREGON%26%23xAE%3B%2C%20deve%20ser%20avaliado%20ante%20os%20riscos.%20Deve-se%20notar%2C%20entretanto%2C%20que%20a%20gravidez%20por%20si%20s%26%23xF3%3B%20tamb%26%23xE9%3Bm%20leva%20ao%20aumento%20do%20risco%20de%20trombose.%3Cbr%3E%20-Gesta%26%23xE7%3B%26%23xF5%3Bes%20e%20nascimentos%20m%26%23xFA%3Bltiplos%20foram%20relatados%20para%20todos%20os%20tratamentos%20com%20gonadotropinas%2C%20incluindo%20PUREGON%26%23xAE%3B.%20As%20gesta%26%23xE7%3B%26%23xF5%3Bes%20m%26%23xFA%3Bltiplas%2C%20especialmente%20de%20alta%20ordem%2C%20implicam%20em%20um%20aumento%20do%20risco%20de%20efeitos%20adversos%20maternos%20(gravidez%20e%20complica%26%23xE7%3B%26%23xF5%3Bes%20no%20parto)%20e%20perinatais%20(baixo%20peso%20ao%20nascer).%20Para%20mulheres%20com%20anovula%26%23xE7%3B%26%23xE3%3Bo%20submetidas%20a%20indu%26%23xE7%3B%26%23xE3%3Bo%20da%20ovula%26%23xE7%3B%26%23xE3%3Bo%2C%20o%20monitoramento%20de%20desenvolvimento%20folicular%20com%20ultrassonografia%20transvaginal%20%26%23xE9%3B%20importante%20para%20minimizar%20o%20risco%20de%20gesta%26%23xE7%3B%26%23xE3%3Bo%20multifetal.%20A%20determina%26%23xE7%3B%26%23xE3%3Bo%20simult%26%23xE2%3Bnea%20das%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20de%20estradiol%20pode%20ser%20%26%23xFA%3Btil.%20As%20pacientes%20dever%26%23xE3%3Bo%20ser%20informadas%20sobre%20os%20riscos%20potenciais%20de%20nascimentos%20m%26%23xFA%3Bltiplos%20antes%20do%20in%26%23xED%3Bcio%20do%20tratamento.%3Cbr%3E%20-Em%20mulheres%20submetidas%20%26%23xE0%3B%20T%26%23xE9%3Bcnica%20de%20Reprodu%26%23xE7%3B%26%23xE3%3Bo%20Assistida%20(TRA)%2C%20o%20risco%20de%20gesta%26%23xE7%3B%26%23xE3%3Bo%20m%26%23xFA%3Bltipla%20%26%23xE9%3B%20relacionado%20principalmente%20ao%20n%26%23xFA%3Bmero%20de%20embri%26%23xF5%3Bes%20transferidos.%20Quando%20usado%20por%20um%20ciclo%20de%20indu%26%23xE7%3B%26%23xE3%3Bo%20da%20ovula%26%23xE7%3B%26%23xE3%3Bo%2C%20ajuste(s)%20apropriado(s)%20da%20dose%20de%20FSH%20deve%20prevenir%20o%20desenvolvimento%20de%20fol%26%23xED%3Bculos%20m%26%23xFA%3Bltiplos.%3Cbr%3E%20-Mulheres%20inf%26%23xE9%3Brteis%20submetidas%20a%20TRA%20t%26%23xEA%3Bm%20um%20aumento%20na%20incid%26%23xEA%3Bncia%20de%20gravidez%20ect%26%23xF3%3Bpica.%20Portanto%2C%20%26%23xE9%3B%20importante%20a%20realiza%26%23xE7%3B%26%23xE3%3Bo%20de%20exame%20ultrassonogr%26%23xE1%3Bfico%20precoce%20para%20confirmar%20se%20a%20gravidez%20%26%23xE9%3B%20intrauterina.%3Cbr%3E%20-A%20incid%26%23xEA%3Bncia%20de%20malforma%26%23xE7%3B%26%23xF5%3Bes%20cong%26%23xEA%3Bnitas%20ap%26%23xF3%3Bs%20TRA%20pode%20ser%20levemente%20maior%20do%20que%20ap%26%23xF3%3Bs%20concep%26%23xE7%3B%26%23xF5%3Bes%20espont%26%23xE2%3Bneas.%20Acredita-seque%20essa%20incid%26%23xEA%3Bncia%20um%20pouco%20aumentada%20se%20deva%20%26%23xE0%3Bs%20diferen%26%23xE7%3Bas%20nas%20caracter%26%23xED%3Bsticas%20dos%20pais%20(por%20exemplo%2C%20idade%20da%20m%26%23xE3%3Be%2C%20caracter%26%23xED%3Bsticas%20do%20esperma)%20e%20%26%23xE0%3B%20maior%20incid%26%23xEA%3Bncia%20de%20gesta%26%23xE7%3B%26%23xF5%3Bes%20m%26%23xFA%3Bltiplas%20ap%26%23xF3%3Bs%20a%20TRA.%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20indica%26%23xE7%3B%26%23xF5%3Bes%20de%20que%20o%20uso%20de%3Cbr%3E%20gonadotropinas%20durante%20a%20TRA%20esteja%20associado%20ao%20aumento%20do%20risco%20de%20malforma%26%23xE7%3B%26%23xF5%3Bes%20cong%26%23xEA%3Bnitas.%3Cbr%3E%20-H%26%23xE1%3B%20relatos%20de%20neoplasmas%20de%20ov%26%23xE1%3Brio%20e%20de%20outros%20do%20sistema%20reprodutor%2C%20tanto%20benigno%20como%20maligno%2C%20em%20mulheres%20que%20foram%20submetidas%20a%20v%26%23xE1%3Brios%20regimes%20de%20tratamento%20para%20infertilidade.%20N%26%23xE3%3Bo%20est%26%23xE1%3B%20estabelecido%20se%20o%20tratamento%20com%20gonadotropinas%20aumenta%20ou%20n%26%23xE3%3Bo%20o%20risco%20desses%20tumores%20em%20mulheres%20inf%26%23xE9%3Brteis.%3Cbr%3E%20-Condi%26%23xE7%3B%26%23xF5%3Bes%20m%26%23xE9%3Bdicas%20que%20contraindiquem%20gravidez%20devem%20ser%20avaliadas%20antes%20do%20in%26%23xED%3Bcio%20do%20tratamento%20com%20PUREGON%26%23xAE%3B.%3Cbr%3E%20Em%20homens%3A%3Cbr%3E%20%26%23x2013%3B%20Concentra%26%23xE7%3B%26%23xF5%3Bes%20elevadas%20de%20FSH%20end%26%23xF3%3Bgeno%20nos%20homens%20s%26%23xE3%3Bo%20indicativos%20de%20insufici%26%23xEA%3Bncia%20testicular%20prim%26%23xE1%3Bria.%20Esses%20pacientes%20n%26%23xE3%3Bo%20respondem%20%26%23xE0%3B%20terapia%20com%20PUREGON%26%23xAE%3B%2FhCG.%3Cbr%3E%20%3Cbr%3E%20Gravidez%20e%20lacta%26%23xE7%3B%26%23xE3%3Bo%3Cbr%3E%20Gravidez%3A%3Cbr%3E%20O%20uso%20de%20PUREGON%26%23xAE%3B%20%26%23xE9%3B%20contraindicado%20durante%20a%20gesta%26%23xE7%3B%26%23xE3%3Bo.%20No%20caso%20de%20exposi%26%23xE7%3B%26%23xE3%3Bo%20inadvertida%20durante%20a%20gesta%26%23xE7%3B%26%23xE3%3Bo%2C%20os%20dados%20cl%26%23xED%3Bnicos%20n%26%23xE3%3Bo%20s%26%23xE3%3Bo%20suficientes%20para%20excluir%20efeito%20teratog%26%23xEA%3Bnico%20do%20FSH%20recombinante.%3Cbr%3E%20Lacta%26%23xE7%3B%26%23xE3%3Bo%3A%3Cbr%3E%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20informa%26%23xE7%3B%26%23xF5%3Bes%20dispon%26%23xED%3Bveis%20de%20estudos%20cl%26%23xED%3Bnicos%20ou%20em%20animais%20de%20excre%26%23xE7%3B%26%23xE3%3Bo%20de%20betafolitropina%20no%20leite.%20%26%23xC9%3B%20pouco%20prov%26%23xE1%3Bvel%20que%20a%20betafolitropina%20seja%20excretada%20no%20leite%20humano%20devido%20ao%20seu%20alto%20peso%20molecular.%20Se%20betafolitropina%20fosse%20excretada%20no%20leite%20humano%2C%20seria%20degradada%20no%20trato%20gastrintestinal%20da%20crian%26%23xE7%3Ba.%20A%20betafolitropina%20pode%20afetar%20a%20produ%26%23xE7%3B%26%23xE3%3Bo%20de%20leite.%3Cbr%3E%20%3Cbr%3E%20Efeitos%20sobre%20a%20habilidade%20de%20dirigir%20e%20operar%20m%26%23xE1%3Bquinas%3Cbr%3E%20N%26%23xE3%3Bo%20foram%20observados%20efeitos%20sobre%20a%20habilidade%20de%20dirigir%20ve%26%23xED%3Bculos%20e%20operar%20m%26%23xE1%3Bquinas.%3Cbr%3E%20%3Cbr%3E%20Pacientes%20idosos%3Cbr%3E%20PUREGON%26%23xAE%3B%20%26%23xE9%3B%20medicamento%20de%20uso%20exclusivo%20para%20pacientes%20em%20idade%20reprodutiva.%20N%26%23xE3%3Bo%20se%20destina%20a%20pacientes%20com%20idade%20%3D%26gt%3B%2060%20anos.%3Cbr%3E%20%3Cbr%3E%20Aten%26%23xE7%3B%26%23xE3%3Bo%3A%20Este%20medicamento%20cont%26%23xE9%3Bm%20a%26%23xE7%3B%26%23xFA%3Bcar%2C%20portanto%2C%20deve%20ser%20usado%20com%20cautela%20em%20portadores%20de%20diabetes.%20Este%20medicamento%20pode%20causar%20doping.%3C%2Fp%3E%0A%3Ch2%3EIntera%26%23xE7%3B%26%23xF5%3Bes%20medicamentosas%20de%20PUREGON%3C%2Fh2%3E%0A%3Cp%3EO%20uso%20concomitante%20de%20PUREGON%26%23xAE%3B%20e%20citrato%20de%20clomifeno%20pode%20aumentar%20a%20resposta%20folicular.%20Ap%26%23xF3%3Bs%20a%20dessensibiliza%26%23xE7%3B%26%23xE3%3Bo%20hipofis%26%23xE1%3Bria%20induzida%20por%20um%20agonista%20do%20GnRH%2C%20pode%20ser%20necess%26%23xE1%3Bria%20uma%20dose%20maior%20de%20PUREGON%26%23xAE%3B%20para%20produzir%20uma%20resposta%20folicular%20adequada.%3Cbr%3E%20Esse%20produto%20n%26%23xE3%3Bo%20deve%20ser%20misturado%20a%20outros%20medicamentos%2C%20uma%20vez%20que%20n%26%23xE3%3Bo%20h%26%23xE1%3B%20estudos%20de%20compatibilidade.%3Cbr%3E%3C%2Fp%3E%0A%3Ch2%3ERea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%2F%20efeitos%20colaterais%20de%20PUREGON%3C%2Fh2%3E%0A%3Cp%3EA%20utiliza%26%23xE7%3B%26%23xE3%3Bo%20cl%26%23xED%3Bnica%20de%20PUREGON%26%23xAE%3B%20tanto%20por%20via%20intramuscular%20quanto%20subcut%26%23xE2%3Bnea%20pode%20levar%20a%20rea%26%23xE7%3B%26%23xF5%3Bes%20no%20local%20da%20aplica%26%23xE7%3B%26%23xE3%3Bo%20(3%25%20de%20todos%20os%20pacientes%20tratados).%20A%20maioria%20dessas%20rea%26%23xE7%3B%26%23xF5%3Bes%20locais%20%26%23xE9%3B%20de%20natureza%20leve%20e%20transit%26%23xF3%3Bria.%20Foram%20observadas%2C%20incomumente%2C%20rea%26%23xE7%3B%26%23xF5%3Bes%20de%20hipersensibilidade%20generalizada%20(aproximadamente%200%2C2%25%20de%20todos%20os%20pacientes%20tratados%20com%20PUREGON%26%23xAE%3B).%3Cbr%3E%20Tratamento%20em%20mulheres%3Cbr%3E%20Durante%20os%20estudos%20cl%26%23xED%3Bnicos%2C%20em%20aproximadamente%204%25%20das%20pacientes%20tratadas%20com%20PUREGON%26%23xAE%3B%2C%20foram%20observados%20sinais%20e%20sintomas%20relacionados%20com%20a%20s%26%23xED%3Bndrome%20de%20hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20(SHEO)%20(ver%20%26%23x93%3B5.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%26%23x94%3B).%20Outros%20efeitos%20indesej%26%23xE1%3Bveis%20relacionados%20com%20essa%20s%26%23xED%3Bndrome%20incluem%3A%20dor%20e%2Fou%20congest%26%23xE3%3Bo%20p%26%23xE9%3Blvica%2C%20dor%20e%2Fou%20distens%26%23xE3%3Bo%20abdominal%2C%20queixas%20mam%26%23xE1%3Brias%20e%20aumento%20ovariano.%3Cbr%3E%20A%20tabela%20a%20seguir%20lista%20as%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20com%20o%20PUREGON%26%23xAE%3B%20relatadas%20nos%20estudos%20cl%26%23xED%3Bnicos%20em%20mulheres%2C%20de%20acordo%20com%20a%20classe%20de%20sistema%20de%20%26%23xF3%3Brg%26%23xE3%3Bos%20e%20frequ%26%23xEA%3Bncia%3A%20comum%20(%3D%26gt%3B%201%2F100%20a%20%26lt%3B%201%2F10)%2C%20incomum%20(%3D%26gt%3B%201%2F1.000%20a%20%26lt%3B%201%2F100).%3Cbr%3E%20%3Cbr%3E%20%3C%2Fp%3E%0A%3Ctable%20border%3D%220%22%3E%0A%3Ctbody%3E%0A%3Ctr%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3E%3Cstrong%3EClasse%20de%20sistema%20de%20%26%23xF3%3Brg%26%23xE3%3Bos%3C%2Fstrong%3E%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3E%3Cstrong%3EFrequ%26%23xEA%3Bncia%3C%2Fstrong%3E%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3E%3Cstrong%3ERea%26%23xE7%3B%26%23xF5%3Bes%20adversas%3C%2Fstrong%3E%3C%2Ftd%3E%0A%3C%2Ftr%3E%0A%3Ctr%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EDist%26%23xFA%3Brbios%20do%20sistema%20nervoso%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EComum%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3ECefaleia%3C%2Ftd%3E%0A%3C%2Ftr%3E%0A%3Ctr%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%20rowspan%3D%222%22%3EDist%26%23xFA%3Brbios%20gastrintestinais%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EComum%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3E%0A%3Cp%3EDistens%26%23xE3%3Bo%20abdominal%3Cbr%3EDor%20abdominal%3C%2Fp%3E%0A%20%20%20%20%20%20%20%20%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Famp-ad%3E%0A%3C%2Ftd%3E%0A%3C%2Ftr%3E%0A%3Ctr%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EIncomum%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3E%0A%3Cp%3EDesconforto%20abdominal%3Cbr%3EConstipa%26%23xE7%3B%26%23xE3%3Bo%3Cbr%3EDiarreia%3Cbr%3EN%26%23xE1%3Busea%3C%2Fp%3E%0A%3C%2Ftd%3E%0A%3C%2Ftr%3E%0A%3Ctr%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%20rowspan%3D%222%22%3EDist%26%23xFA%3Brbios%20do%20sistema%20reprodutor%20e%20mamas%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EComum%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3E%0A%3Cp%3ES%26%23xED%3Bndrome%20de%20hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20(SHEO)%3Cbr%3EDor%20p%26%23xE9%3Blvica%3C%2Fp%3E%0A%3C%2Ftd%3E%0A%3C%2Ftr%3E%0A%3Ctr%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EIncomum%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3E%0A%3Cp%3EQueixas%20mam%26%23xE1%3Brias1%3Cbr%3EMetrorragia%3Cbr%3ECistos%20ovarianos%3Cbr%3EAumento%20do%20volume%20ovariano%3Cbr%3ETor%26%23xE7%3B%26%23xE3%3Bo%20ovariana%3Cbr%3EAumento%20do%20volume%20uterino%3Cbr%3ESangramento%20vaginal%3C%2Fp%3E%0A%3C%2Ftd%3E%0A%3C%2Ftr%3E%0A%3Ctr%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%20rowspan%3D%222%22%3EDist%26%23xFA%3Brbios%20gerais%20e%20condi%26%23xE7%3B%26%23xF5%3Bes%20no%20local%20da%20administra%26%23xE7%3B%26%23xE3%3Bo%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EComum%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3ERea%26%23xE7%3B%26%23xE3%3Bo%20no%20local%20de%20inje%26%23xE7%3B%26%23xE3%3Bo2%3C%2Ftd%3E%0A%3C%2Ftr%3E%0A%3Ctr%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EIncomum%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3ERea%26%23xE7%3B%26%23xE3%3Bo%20de%20hipersensibilidade%20generalizada3%3C%2Ftd%3E%0A%3C%2Ftr%3E%0A%3C%2Ftbody%3E%0A%3C%2Ftable%3E%0A%3Cp%3E%3Cbr%3E%20%3Cbr%3E%201.Queixas%20mam%26%23xE1%3Brias%20incluem%3A%20sensibilidade%2C%20dor%20e%2Fou%20ingurgitamento%20e%20dor%20nos%20mamilos.%3Cbr%3E%202.Rea%26%23xE7%3B%26%23xF5%3Bes%20no%20local%20da%20inje%26%23xE7%3B%26%23xE3%3Bo%20incluem%3A%20hematoma%2C%20dor%2C%20vermelhid%26%23xE3%3Bo%2C%20incha%26%23xE7%3Bo%20e%20coceira.%3Cbr%3E%203.Rea%26%23xE7%3B%26%23xE3%3Bo%20de%20hipersensibilidade%20generalizada%20inclue%3A%20eritema%2C%20urtic%26%23xE1%3Bria%2C%20exantema%20e%20prurido.%3Cbr%3E%20Adicionalmente%2C%20gravidez%20ect%26%23xF3%3Bpica%2C%20aborto%20e%20gesta%26%23xE7%3B%26%23xE3%3Bo%20m%26%23xFA%3Bltipla%20foram%20reportados.%20Estas%20rea%26%23xE7%3B%26%23xF5%3Bes%20s%26%23xE3%3Bo%20consideradas%20relacionadas%20as%20T%26%23xE9%3Bcnicas%20de%20Reprodu%26%23xE7%3B%26%23xE3%3Bo%20Assistida%20(TRA)%20ou%20gravidez%20subsequente.%3Cbr%3E%20Em%20casos%20raros%2C%20tromboembolismo%20foi%20associado%20ao%20tratamento%20com%20PUREGON%26%23xAE%3B%2FhCG%2C%20assim%20como%20com%20outras%20gonadotropinas.%3Cbr%3E%20Tratamento%20em%20homens%3Cbr%3E%20A%20tabela%20abaixo%20lista%20as%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20com%20PUREGON%26%23xAE%3B%20relatadas%20nos%20estudos%20cl%26%23xED%3Bnicos%20em%20homens%20(30%20pacientes%20avaliados)%2C%20de%20acordo%20com%20a%20classe%20de%20sistema%20de%20%26%23xF3%3Brg%26%23xE3%3Bos%20e%20frequ%26%23xEA%3Bncia%3A%20comum%20(%3D%26gt%3B%201%2F100%20a%20%26lt%3B%201%2F10).%3Cbr%3E%20%3Cbr%3E%20%3C%2Fp%3E%0A%20%20%20%20%20%20%20%20%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Famp-ad%3E%0A%3Ctable%20border%3D%220%22%3E%0A%3Ctbody%3E%0A%3Ctr%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3E%3Cstrong%3EClasse%20de%20sistema%20de%20%26%23xF3%3Brg%26%23xE3%3Bos%3C%2Fstrong%3E%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3E%3Cstrong%3EFrequ%26%23xEA%3Bncia1%3C%2Fstrong%3E%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3E%3Cstrong%3ERea%26%23xE7%3B%26%23xF5%3Bes%20Adversas%3C%2Fstrong%3E%3C%2Ftd%3E%0A%3C%2Ftr%3E%0A%3Ctr%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EDist%26%23xFA%3Brbios%20do%20sistema%20nervoso%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EComum%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3ECefaleia%3C%2Ftd%3E%0A%3C%2Ftr%3E%0A%3Ctr%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EDist%26%23xFA%3Brbios%20na%20pele%20e%20nos%20tecidos%20subcut%26%23xE2%3Bneos%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EComum%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3E%0A%3Cp%3EAcne%3Cbr%3EErup%26%23xE7%3B%26%23xE3%3Bo%20cut%26%23xE2%3Bnea%3C%2Fp%3E%0A%3C%2Ftd%3E%0A%3C%2Ftr%3E%0A%3Ctr%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EDist%26%23xFA%3Brbios%20do%20sistema%20reprodutor%20e%20da%20mama%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EComum%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3E%0A%3Cp%3ECisto%20do%20epid%26%23xED%3Bdimo%3Cbr%3EGinecomastia%3C%2Fp%3E%0A%3C%2Ftd%3E%0A%3C%2Ftr%3E%0A%3Ctr%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EDist%26%23xFA%3Brbios%20em%20geral%20e%20condi%26%23xE7%3B%26%23xF5%3Bes%20no%20local%20da%20administra%26%23xE7%3B%26%23xE3%3Bo%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EComum%3C%2Ftd%3E%0A%3Ctd%20style%3D%22border%3A1px%20solid%20black%3Bpadding%3A%205px%3B%22%3EEndurecimento%20no%20local%20de%20inje%26%23xE7%3B%26%23xE3%3Bo%3C%2Ftd%3E%0A%3C%2Ftr%3E%0A%3C%2Ftbody%3E%0A%3C%2Ftable%3E%0A%3Cp%3E%3Cbr%3E%20%3Cbr%3E%201.%20Rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20que%20s%26%23xE3%3Bo%20relatadas%20somente%20uma%20vez%20s%26%23xE3%3Bo%20listadas%20como%20comum%20pois%20um%20%26%23xFA%3Bnico%20relato%20eleva%20a%20frequ%26%23xEA%3Bncia%20acima%20de%201%25.%3Cbr%3E%20%3Cbr%3E%20Em%20casos%20de%20eventos%20adversos%2C%20notifique%20ao%20Sistema%20de%20Notifica%26%23xE7%3B%26%23xF5%3Bes%20em%20Vigil%26%23xE2%3Bncia%20Sanit%26%23xE1%3Bria%20%26%23x2013%3B%20NOTIVISA%2C%20dispon%26%23xED%3Bvel%20em%20www.anvisa.gov.br%2Fhotsite%2Fnotivisa%2Findex.htm%2C%20ou%20para%20a%20Vigil%26%23xE2%3Bncia%20Sanit%26%23xE1%3Bria%20Estadual%20ou%20Municipal.%3C%2Fp%3E%0A%3Ch2%3EPUREGON%20%26%23x2013%3B%20Posologia%3C%2Fh2%3E%0A%3Cp%3EPosologia%3Cbr%3E%20O%20tratamento%20com%20PUREGON%26%23xAE%3B%20deve%20ser%20iniciado%20sob%20supervis%26%23xE3%3Bo%20de%20um%20m%26%23xE9%3Bdico%20com%20experi%26%23xEA%3Bncia%20no%20tratamento%20de%20problemas%20de%20fertilidade.%3Cbr%3E%20As%20inje%26%23xE7%3B%26%23xF5%3Bes%20iniciais%20de%20PUREGON%26%23xAE%3B%20devem%20ser%20aplicadas%20apenas%20sob%20supervis%26%23xE3%3Bo%20m%26%23xE9%3Bdica.%3Cbr%3E%20Ao%20utilizar%20a%20caneta%20injetora%20deve-se%20ter%20em%20mente%20que%20este%20%26%23xE9%3B%20um%20instrumento%20de%20precis%26%23xE3%3Bo%20que%20libera%20exatamente%20a%20dose%20para%20a%20qual%20foi%20ajustado.%20Foi%20demonstrado%20que%20em%20m%26%23xE9%3Bdia%20uma%20quantidade%2018%25%20maior%20de%20FSH%20%26%23xE9%3B%20administrada%20com%20a%20caneta%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%20a%20seringa%20convencional.%20Isso%20pode%20ser%20de%20particular%20relev%26%23xE2%3Bncia%20quando%20se%20alterna%20entre%20PUREGON%20PEN%26%23xAE%3B%20e%20a%20seringa%20convencional%20em%20um%20mesmo%20ciclo%20de%20tratamento.%20Especialmente%20quando%20se%20muda%20da%20seringa%20para%20a%20caneta%2C%20podem%20ser%20necess%26%23xE1%3Brios%20pequenos%20ajustes%20de%20dose%20para%20evitar%20que%20seja%20administrada%20dose%20muito%20alta.%3Cbr%3E%20%3Cbr%3E%20Dose%20para%20mulheres%3Cbr%3E%20Existem%20grandes%20varia%26%23xE7%3B%26%23xF5%3Bes%20inter%20e%20intraindividuais%20na%20resposta%20dos%20ov%26%23xE1%3Brios%20%26%23xE0%3Bs%20gonadotropinas%20ex%26%23xF3%3Bgenas.%20Por%20isso%2C%20%26%23xE9%3B%20imposs%26%23xED%3Bvel%20estabelecer%20um%20esquema%20de%20dosagem%20uniforme.%20Portanto%2C%20o%20ajuste%20deve%20ser%20feito%20individualmente%20dependendo%20da%20resposta%20ovariana.%20Para%20isso%2C%20%26%23xE9%3B%20necess%26%23xE1%3Brio%20avalia%26%23xE7%3B%26%23xE3%3Bo%20por%20ultrassonografia%20do%20desenvolvimento%20folicular.%20A%20determina%26%23xE7%3B%26%23xE3%3Bo%20simult%26%23xE2%3Bnea%20das%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20de%20estradiol%20pode%20ser%20%26%23xFA%3Btil.%3Cbr%3E%20Estudos%20cl%26%23xED%3Bnicos%20comparativos%20entre%20PUREGON%26%23xAE%3B%20e%20FSH%20urin%26%23xE1%3Brio%20mostraram%20que%20PUREGON%26%23xAE%3B%20%26%23xE9%3B%20mais%20eficaz%20que%20o%20FSH%20urin%26%23xE1%3Brio%20em%20termos%20de%20dose%20total%20mais%20baixa%20e%20per%26%23xED%3Bodo%20de%20tratamento%20mais%20curto%2C%20necess%26%23xE1%3Brio%20para%20atingir%20as%20condi%26%23xE7%3B%26%23xF5%3Bes%20pr%26%23xE9%3B-ovulat%26%23xF3%3Brias.%20Portanto%2C%20considera-se%20adequado%20administrar%20doses%20menores%20de%20PUREGON%26%23xAE%3B%20do%20que%20a%20geralmente%20usada%20para%20FSH%20urin%26%23xE1%3Brio%2C%20n%26%23xE3%3Bo%20somente%20para%20otimizar%20o%20desenvolvimento%20folicular%2C%20mas%20tamb%26%23xE9%3Bm%20para%20reduzir%20o%20risco%20de%20hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20indesejada.%3Cbr%3E%20A%20experi%26%23xEA%3Bncia%20cl%26%23xED%3Bnica%20com%20PUREGON%26%23xAE%3B%20%26%23xE9%3B%20baseada%20em%20at%26%23xE9%3B%20tr%26%23xEA%3Bs%20ciclos%20de%20tratamento%20nas%20duas%20indica%26%23xE7%3B%26%23xF5%3Bes.%20A%20experi%26%23xEA%3Bncia%20cl%26%23xED%3Bnica%20geral%20em%20FIV%20indica%20que%20o%20%26%23xED%3Bndice%20de%20sucesso%20terap%26%23xEA%3Butico%20permanece%20est%26%23xE1%3Bvel%20durante%20as%20primeiras%20quatro%20tentativas%20e%2C%20depois%2C%20declina%20gradualmente.%3Cbr%3E%20%3Cbr%3E%20%26%23x2212%3BAnovula%26%23xE7%3B%26%23xE3%3Bo%3Cbr%3E%20Recomenda-se%20um%20esquema%20de%20tratamento%20sequencial%2C%20geralmente%20iniciado%20com%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20di%26%23xE1%3Bria%20de%2050%20UI%20de%20PUREGON%26%23xAE%3B.%20Essa%20dose%20inicial%20deve%20ser%20mantida%20por%2C%20no%20m%26%23xED%3Bnimo%2C%20sete%20dias.%20Se%20n%26%23xE3%3Bo%20for%20detectada%20resposta%20dos%20ov%26%23xE1%3Brios%2C%20a%20dose%20di%26%23xE1%3Bria%20deve%20ser%20aumentada%20gradualmente%20at%26%23xE9%3B%20o%20crescimento%20folicular%20e%2Fou%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20de%20estradiol%20indicarem%20resposta%20farmacodin%26%23xE2%3Bmica%20adequada.%20Um%20aumento%20das%20concentra%26%23xE7%3B%26%23xF5%3Bes%20de%20estradiol%20de%2040%20a%20100%25%20ao%20dia%20%26%23xE9%3B%20considerado%20%26%23xF3%3Btimo.%20A%20dose%20di%26%23xE1%3Bria%20%26%23xE9%3B%2C%20ent%26%23xE3%3Bo%2C%20mantida%20at%26%23xE9%3B%20que%20sejam%20atingidas%20as%20condi%26%23xE7%3B%26%23xF5%3Bes%20de%20pr%26%23xE9%3B-ovula%26%23xE7%3B%26%23xE3%3Bo.%20As%20condi%26%23xE7%3B%26%23xF5%3Bes%20pr%26%23xE9%3B-ovulat%26%23xF3%3Brias%20s%26%23xE3%3Bo%20atingidas%20quando%20h%26%23xE1%3B%20evid%26%23xEA%3Bncia%20ultrassonogr%26%23xE1%3Bfica%20de%20um%20fol%26%23xED%3Bculo%20dominante%20de%2C%20pelo%20menos%2C%2018%20mm%20de%20di%26%23xE2%3Bmetro%20e%2Fou%20quando%20s%26%23xE3%3Bo%20atingidas%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20de%20estradiol%20de%20300%20a%20900%20picogramas%2FmL%20(1000%20a%203000%20pmol%2FL).%20Normalmente%20s%26%23xE3%3Bo%20suficientes%20de%207%20a%2014%20dias%20de%20tratamento%20para%20atingir%20esse%20n%26%23xED%3Bvel.%20A%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20PUREGON%26%23xAE%3B%20%26%23xE9%3B%2C%20ent%26%23xE3%3Bo%2C%20interrompida%20e%20pode-se%20induzir%20a%20ovula%26%23xE7%3B%26%23xE3%3Bo%2C%20administrando-se%20gonadotropina%20cori%26%23xF4%3Bnica%20humana%20(hCG).%20Se%20o%20n%26%23xFA%3Bmero%20de%20fol%26%23xED%3Bculos%20responsivos%20for%20muito%20alto%20ou%20se%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20de%20estradiol%20aumentarem%20muito%20rapidamente%2C%20por%20exemplo%2C%20mais%20que%20o%20dobro%20de%20estradiol%20ao%20dia%20durante%20dois%20ou%20tr%26%23xEA%3Bs%20dias%20consecutivos%2C%20a%20dose%20di%26%23xE1%3Bria%20dever%26%23xE1%3B%20ser%20diminu%26%23xED%3Bda.%3Cbr%3E%20Como%20os%20fol%26%23xED%3Bculos%20com%20mais%20de%2014%20mm%20podem%20resultar%20em%20gesta%26%23xE7%3B%26%23xE3%3Bo%2C%20m%26%23xFA%3Bltiplos%20fol%26%23xED%3Bculos%20pr%26%23xE9%3B-ovulat%26%23xF3%3Brios%20com%20mais%20de%2014%20mm%20aumentam%20o%20risco%20de%20gesta%26%23xE7%3B%26%23xE3%3Bo%20m%26%23xFA%3Bltipla.%20Nesse%20caso%2C%20deve-se%20suspender%20a%20hCG%20e%20evitar%20a%20gesta%26%23xE7%3B%26%23xE3%3Bo%20para%20impedir%20gesta%26%23xE7%3B%26%23xF5%3Bes%20m%26%23xFA%3Bltiplas.%3Cbr%3E%20%3Cbr%3E%20%26%23x2212%3BHiperestimula%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20controlada%20em%20programas%20de%20reprodu%26%23xE7%3B%26%23xE3%3Bo%20assistida%3Cbr%3E%20V%26%23xE1%3Brios%20protocolos%20de%20estimula%26%23xE7%3B%26%23xE3%3Bo%20podem%20ser%20empregados.%20Uma%20dose%20inicial%20de%20100%20a%20225%20UI%20%26%23xE9%3B%20recomendada%20pelo%20menos%20nos%20primeiros%20quatro%20dias%20de%20estimula%26%23xE7%3B%26%23xE3%3Bo.%20Da%26%23xED%3B%20em%20diante%2C%20a%20dose%20deve%20ser%20ajustada%20individualmente%2C%20baseada%20na%20resposta%20ovariana.%20Estudos%20cl%26%23xED%3Bnicos%20demonstraram%20que%20doses%20de%20manuten%26%23xE7%3B%26%23xE3%3Bo%20variando%20entre%2075%20a%20375%20UI%20por%20seis%20a%20doze%20dias%20s%26%23xE3%3Bo%20suficientes%2C%20embora%20tratamentos%20mais%20longos%20possam%20ser%20necess%26%23xE1%3Brios.%3Cbr%3E%20PUREGON%26%23xAE%3B%20pode%20ser%20usado%20isoladamente%20ou%20em%20combina%26%23xE7%3B%26%23xE3%3Bo%20com%20antagonista%20ou%20agonista%20do%20GnRH%20para%20prevenir%20a%20luteiniza%26%23xE7%3B%26%23xE3%3Bo%20prematura.%20Ao%20utilizar%20um%20agonista%20do%20GnRH%20pode%20ser%20necess%26%23xE1%3Brio%20um%20tratamento%20com%20dose%20total%20maior%20de%20PUREGON%26%23xAE%3B%20para%20atingir%20uma%20resposta%20folicular%20adequada.%3Cbr%3E%20A%20resposta%20ovariana%20%26%23xE9%3B%20monitorada%20por%20avalia%26%23xE7%3B%26%23xE3%3Bo%20ultrassonogr%26%23xE1%3Bfica.%20A%20determina%26%23xE7%3B%26%23xE3%3Bo%20simult%26%23xE2%3Bnea%20de%20concentra%26%23xE7%3B%26%23xF5%3Bes%20s%26%23xE9%3Bricas%20de%20estradiol%20pode%20ser%20%26%23xFA%3Btil.%20Quando%20a%20avalia%26%23xE7%3B%26%23xE3%3Bo%20ultrassonogr%26%23xE1%3Bfica%20indicar%20a%20presen%26%23xE7%3Ba%20de%2C%20ao%20menos%2C%20tr%26%23xEA%3Bs%20fol%26%23xED%3Bculos%20de%2016%20a%2020%20mm%2C%20e%20a%20resposta%20de%20estradiol%20for%20boa%20%5Bconcentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20de%20aproximadamente%20300%20a%20400%20picogramas%2FmL%20(1000%20a%201300%20pmol%2FL)%20para%20cada%20fol%26%23xED%3Bculo%20com%20um%20di%26%23xE2%3Bmetro%20maior%20que%2018%20mm%5D%2C%20faz-se%20a%20indu%26%23xE7%3B%26%23xE3%3Bo%20da%20fase%20final%20da%20matura%26%23xE7%3B%26%23xE3%3Bo%20folicular%20administrando-sehCG.%20A%20capta%26%23xE7%3B%26%23xE3%3Bo%20dos%20o%26%23xF3%3Bcitos%20%26%23xE9%3B%20realizada%20ap%26%23xF3%3Bs%2034%20a%2035%20horas.%3Cbr%3E%20%3Cbr%3E%20Dose%20para%20homens%3Cbr%3E%20PUREGON%26%23xAE%3B%20dever%26%23xE1%3B%20ser%20administrado%20na%20dose%20de%20450%20UI%2Fsemana%2C%20preferencialmente%20dividida%20em%20tr%26%23xEA%3Bs%20doses%20de%20150%20UI%2C%20associado%20com%20hCG.%20O%20tratamento%20com%20PUREGON%26%23xAE%3B%20e%20hCG%20deve%20continuar%20por%2C%20pelo%20menos%2C%203%20a%204%20meses%20antes%20que%20qualquer%20melhora%20na%20espermatog%26%23xEA%3Bnese%20possa%20ser%20esperada.%20Para%20avaliar%20a%20resposta%2C%20a%20an%26%23xE1%3Blise%20de%20s%26%23xEA%3Bmen%20%26%23xE9%3B%20recomendada%204%20a%206%20meses%20ap%26%23xF3%3Bs%20o%20in%26%23xED%3Bcio%20do%20tratamento.%20Se%20um%20paciente%20n%26%23xE3%3Bo%20apresentar%20resposta%20ap%26%23xF3%3Bs%20esse%20per%26%23xED%3Bodo%2C%20a%20terapia%20combinada%20poder%26%23xE1%3B%20ser%20continuada%3B%20a%20experi%26%23xEA%3Bncia%20cl%26%23xED%3Bnica%20atual%20indica%20que%20o%20tratamento%20de%20at%26%23xE9%3B%2018%20meses%20ou%20mais%20poder%26%23xE1%3B%20ser%20necess%26%23xE1%3Brio%20para%20se%20atingir%20a%20espermatog%26%23xEA%3Bnese.%3Cbr%3E%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20indica%26%23xE7%3B%26%23xE3%3Bo%20para%20o%20uso%20de%20PUREGON%26%23xAE%3B%20em%20crian%26%23xE7%3Bas.%3Cbr%3E%20%3Cbr%3E%20Modo%20de%20usar%3Cbr%3E%20PUREGON%26%23xAE%3B%20solu%26%23xE7%3B%26%23xE3%3Bo%20injet%26%23xE1%3Bvel%20em%20carpules%20foi%20desenvolvido%20para%20ser%20utilizado%20em%20conjunto%20com%20a%20caneta%20injetora%20PUREGON%20PEN%26%23xAE%3B%20e%20deve%20ser%20administrado%20por%20via%20subcut%26%23xE2%3Bnea.%20As%20instru%26%23xE7%3B%26%23xF5%3Bes%20de%20uso%20da%20caneta%20devem%20ser%20seguidas%20cuidadosamente.%3Cbr%3E%20O%20local%20de%20aplica%26%23xE7%3B%26%23xE3%3Bo%20da%20inje%26%23xE7%3B%26%23xE3%3Bo%20deve%20ser%20alternado%20para%20evitar%20lipoatrofia.%3Cbr%3E%20Utilizando%20a%20caneta%20injetora%2C%20a%20inje%26%23xE7%3B%26%23xE3%3Bo%20de%20PUREGON%26%23xAE%3B%20pode%20ser%20feita%20pelo%20paciente%20ou%20seu%20parceiro(a)%2C%20desde%20que%20as%20instru%26%23xE7%3B%26%23xF5%3Bes%20necess%26%23xE1%3Brias%20sejam%20fornecidas%20pelo%20m%26%23xE9%3Bdico.%20A%20autoadministra%26%23xE7%3B%26%23xE3%3Bo%20de%20PUREGON%26%23xAE%3B%20somente%20deve%20ser%20realizada%20por%20pacientes%20bem%20motivados%2C%20adequadamente%20treinados%20e%20com%20acesso%20a%20aconselhamento%20especializado.%3Cbr%3E%20PUREGON%26%23xAE%3B%20carpules%20n%26%23xE3%3Bo%20dever%26%23xE1%3B%20ser%20utilizado%20caso%20a%20solu%26%23xE7%3B%26%23xE3%3Bo%20contenha%20part%26%23xED%3Bculas%20ou%20n%26%23xE3%3Bo%20estiver%20l%26%23xED%3Bmpida.%20Se%20houver%20bolhas%20de%20ar%20na%20carpule%2C%20elas%20devem%20ser%20eliminadas%20antes%20da%20inje%26%23xE7%3B%26%23xE3%3Bo%20(vide%20Instru%26%23xE7%3B%26%23xF5%3Bes%20de%20Uso%20de%20PUREGON%20PEN%26%23xAE%3B).%3Cbr%3E%20Descartar%20as%20agulhas%20usadas%20imediatamente%20ap%26%23xF3%3Bs%20a%20inje%26%23xE7%3B%26%23xE3%3Bo.%3Cbr%3E%20Descartar%20as%20carpules%20(incluindo%20o%20volume%20restante%20de%20solu%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20utiliz%26%23xE1%3Bvel)%20ap%26%23xF3%3Bs%20a%20%26%23xFA%3Bltima%20inje%26%23xE7%3B%26%23xE3%3Bo%20do%20ciclo%20de%20tratamento.%20As%20carpules%20vazias%20n%26%23xE3%3Bo%20podem%20ser%20recarregadas.%20Nenhum%20outro%20f%26%23xE1%3Brmaco%20dever%26%23xE1%3B%20ser%20misturado%20%26%23xE0%3B%20carpule%20de%20PUREGON%26%23xAE%3B%20solu%26%23xE7%3B%26%23xE3%3Bo.%3C%2Fp%3E%0A%20%20%20%20%20%20%20%20%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Famp-ad%3E%0A%3Ch2%3ESuper%20dosagem%3C%2Fh2%3E%0A%3Cp%3EN%26%23xE3%3Bo%20existem%20dados%20sobre%20a%20toxicidade%20aguda%20de%20PUREGON%26%23xAE%3B%20em%20seres%20humanos%2C%20mas%20foi%20demonstrado%20que%20a%20toxicidade%20aguda%20de%20PUREGON%26%23xAE%3B%20e%20de%20prepara%26%23xE7%3B%26%23xF5%3Bes%20com%20gonadotropina%20urin%26%23xE1%3Bria%2C%20em%20estudos%20em%20animais%20%26%23xE9%3B%20muito%20baixa.%20Uma%20dose%20muito%20alta%20de%20FSH%20pode%20conduzir%20%26%23xE0%3B%20hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20dos%20ov%26%23xE1%3Brios%20(SHEO)%20(ver%20%26%23x93%3B5.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%20%26%23x96%3B%20Hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20indesejada%26%23x94%3B).%3Cbr%3E%20%3Cbr%3E%20Em%20caso%20de%20intoxica%26%23xE7%3B%26%23xE3%3Bo%20ligue%20para%200800%20722%206001%2C%20se%20voc%26%23xEA%3B%20precisar%20de%20mais%20orienta%26%23xE7%3B%26%23xF5%3Bes.%3Cbr%3E%3C%2Fp%3E%0A%3Ch2%3ECaracteristicas%20farmalogicas%3C%2Fh2%3E%0A%3Cp%3EPropriedades%20farmacodin%26%23xE2%3Bmicas%3Cbr%3E%20Grupo%20farmacoterap%26%23xEA%3Butico%3A%20gonadotropinas%3B%20c%26%23xF3%3Bdigo%20ATC%3A%20G03G%20A06.%3Cbr%3E%20PUREGON%26%23xAE%3B%20cont%26%23xE9%3Bm%20FSH%20(horm%26%23xF4%3Bnio%20fol%26%23xED%3Bculo%20estimulante)%20recombinante%20(FSHr)%20produzido%20pela%20t%26%23xE9%3Bcnica%20de%20DNA%20recombinante%2C%20usando-se%20uma%20linhagem%20de%20c%26%23xE9%3Blulas%20de%20ov%26%23xE1%3Brio%20de%20hamster%20chin%26%23xEA%3Bs%20transfectada%20com%20subunidades%20de%20genes%20de%20FSH%20humano.%20A%20sequ%26%23xEA%3Bncia%20prim%26%23xE1%3Bria%20de%20amino%26%23xE1%3Bcidos%20%26%23xE9%3B%20id%26%23xEA%3Bntica%20%26%23xE0%3B%20do%20FSH%20humano%20natural.%20Existem%20pequenas%20diferen%26%23xE7%3Bas%20na%20estrutura%20da%20cadeia%20de%20carboidratos.%3Cbr%3E%20O%20FSH%20%26%23xE9%3B%20indispens%26%23xE1%3Bvel%20para%20o%20crescimento%20e%20matura%26%23xE7%3B%26%23xE3%3Bo%20folicular%20normais%20e%20para%20a%20produ%26%23xE7%3B%26%23xE3%3Bo%20de%20esteroides%20gonadais.%20Na%20mulher%2C%20a%20quantidade%20de%20FSH%20%26%23xE9%3B%20determinante%20para%20o%20in%26%23xED%3Bcio%20e%20dura%26%23xE7%3B%26%23xE3%3Bo%20do%20desenvolvimento%20folicular%20e%2C%20consequentemente%2C%20para%20o%20tempo%20de%20amadurecimento%20e%20n%26%23xFA%3Bmero%20de%20fol%26%23xED%3Bculos%20que%20atingem%20a%20maturidade.%20Portanto%2C%20PUREGON%26%23xAE%3B%20pode%20ser%20utilizado%20para%20estimular%20o%20desenvolvimento%20folicular%20e%20a%20produ%26%23xE7%3B%26%23xE3%3Bo%20de%20esteroides%20em%20casos%20selecionados%20de%20altera%26%23xE7%3B%26%23xF5%3Bes%20da%20fun%26%23xE7%3B%26%23xE3%3Bo%20gonadal.%20Al%26%23xE9%3Bm%20disso%2C%20PUREGON%26%23xAE%3B%20pode%20ser%20utilizado%20para%20promover%20o%20desenvolvimento%20folicular%20m%26%23xFA%3Bltiplo%20em%20programas%20de%20reprodu%26%23xE7%3B%26%23xE3%3Bo%20assistida%20%5Bpor%20exemplo%2C%20fertiliza%26%23xE7%3B%26%23xE3%3Bo%20in%20vitro%2Ftransfer%26%23xEA%3Bncia%20de%20embri%26%23xF5%3Bes%20(FIV%2FTE)%2C%20transfer%26%23xEA%3Bncia%20intratub%26%23xE1%3Bria%20de%20gametas%20(GIFT)%20e%20inje%26%23xE7%3B%26%23xE3%3Bo%20intracitoplasm%26%23xE1%3Btica%20de%20espermatozoides%20(ICSI)%5D.%20O%20tratamento%20com%20PUREGON%26%23xAE%3B%20%26%23xE9%3B%2C%20geralmente%2C%20seguido%20pela%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20gonadotropina%20cori%26%23xF4%3Bnica%20humana%20(hCG)%20para%20induzir%20a%20fase%20final%20da%20matura%26%23xE7%3B%26%23xE3%3Bo%20folicular%2C%20retomada%20da%20meiose%20e%20ruptura%20do%20fol%26%23xED%3Bculo.%3Cbr%3E%20%3Cbr%3E%20Propriedades%20farmacocin%26%23xE9%3Bticas%3Cbr%3E%20Ap%26%23xF3%3Bs%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20intramuscular%20ou%20subcut%26%23xE2%3Bnea%20de%20PUREGON%26%23xAE%3B%2C%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20m%26%23xE1%3Bximas%20de%20FSH%20s%26%23xE3%3Bo%20alcan%26%23xE7%3Badas%20em%20aproximadamente%2012%20horas.%20Ap%26%23xF3%3Bs%20administra%26%23xE7%3B%26%23xE3%3Bo%20intramuscular%20de%20PUREGON%26%23xAE%3B%2C%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20m%26%23xE1%3Bximas%20de%20FSH%20s%26%23xE3%3Bo%20mais%20elevadas%20e%20atingidas%20mais%20precocemente%20em%20homens%20do%20que%20em%20mulheres.%20Por%20causa%20da%20libera%26%23xE7%3B%26%23xE3%3Bo%20prolongada%20a%20partir%20do%20local%20de%20administra%26%23xE7%3B%26%23xE3%3Bo%20e%20da%20meia-vida%20de%20elimina%26%23xE7%3B%26%23xE3%3Bo%20de%20aproximadamente%2040%20horas%20(variando%20de%2012%20a%2070%20horas)%2C%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20de%20FSH%20permanecem%20elevados%20durante%2024%20a%2048%20horas.%20Devido%20%26%23xE0%3B%20meia-vida%20de%20elimina%26%23xE7%3B%26%23xE3%3Bo%20relativamente%20longa%2C%20ap%26%23xF3%3Bs%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20repetida%20da%20mesma%20dose%2C%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20de%20FSH%20no%20plasma%20s%26%23xE3%3Bo%20aproximadamente%201%2C5%20a%202%2C5%20vezes%20maiores%20do%20que%20ap%26%23xF3%3Bs%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20%26%23xFA%3Bnica.%20Esse%20aumento%20permite%20que%20sejam%20alcan%26%23xE7%3Badas%20concentra%26%23xE7%3B%26%23xF5%3Bes%20terap%26%23xEA%3Buticas%20de%20FSH.%3Cbr%3E%20N%26%23xE3%3Bo%20existem%20diferen%26%23xE7%3Bas%20farmacocin%26%23xE9%3Bticas%20significativas%20entre%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20subcut%26%23xE2%3Bnea%20e%20intramuscular%20de%20PUREGON%26%23xAE%3B.%20Ambas%20t%26%23xEA%3Bm%20biodisponibilidade%20absoluta%20de%20aproximadamente%2077%25.%20O%20FSH%20recombinante%20%26%23xE9%3B%20bioquimicamente%20muito%20similar%20ao%20FSH%20urin%26%23xE1%3Brio%20humano%20e%20%26%23xE9%3B%20distribu%26%23xED%3Bdo%2C%20metabolizado%20e%20excretado%20pelas%20mesmas%20vias.%3Cbr%3E%20%3Cbr%3E%20Dados%20de%20seguran%26%23xE7%3Ba%20pr%26%23xE9%3B-cl%26%23xED%3Bnicos%3Cbr%3E%20A%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20dose%20%26%23xFA%3Bnica%20de%20PUREGON%26%23xAE%3B%20em%20ratos%20n%26%23xE3%3Bo%20induziu%20efeitos%20toxicol%26%23xF3%3Bgicos%20significativos.%20Em%20estudos%20de%20dose%20repetida%20em%20ratos%20(duas%20semanas)%20e%20c%26%23xE3%3Bes%20(13%20semanas)%20com%20at%26%23xE9%3B%20100%20vezes%20a%20dose%20terap%26%23xEA%3Butica%20m%26%23xE1%3Bxima%20humana%2C%20PUREGON%26%23xAE%3B%20n%26%23xE3%3Bo%20induziu%20efeitos%20toxicol%26%23xF3%3Bgicos%20significativos.%20PUREGON%26%23xAE%3B%20n%26%23xE3%3Bo%20apresentou%20potencial%20mutag%26%23xEA%3Bnico%20no%20teste%20de%20Ames%20e%20em%20teste%20de%20aberra%26%23xE7%3B%26%23xE3%3Bo%20cromoss%26%23xF4%3Bmica%20in%20vitro%20com%20linf%26%23xF3%3Bcitos%20humanos.%3C%2Fp%3E%0A%3Ch2%3EResultados%20de%20eficacia%3C%2Fh2%3E%0A%3Cp%3EMulheres%3Cbr%3E%20A%20efic%26%23xE1%3Bcia%20de%20PUREGON%26%23xAE%3B%20foi%20estabelecida%20em%20quatro%20estudos%20cl%26%23xED%3Bnicos%20controlados%20%5Btr%26%23xEA%3Bs%20estudos%20para%20T%26%23xE9%3Bcnicas%20de%20Reprodu%26%23xE7%3B%26%23xE3%3Bo%20Assistida%20(TRA)%20e%20um%20estudo%20para%20a%20Indu%26%23xE7%3B%26%23xE3%3Bo%20da%20Ovula%26%23xE7%3B%26%23xE3%3Bo%5D%2C%20tr%26%23xEA%3Bs%20dos%20quais%20est%26%23xE3%3Bo%20descritos%20a%20seguir.%20Nesses%20estudos%20comparativos%2C%20n%26%23xE3%3Bo%20houve%20diferen%26%23xE7%3Bas%20clinicamente%20significativas%20entre%20os%20grupos%20de%20tratamento%20nos%20resultados%20do%20estudo.%3Cbr%3E%20%3Cbr%3E%20T%26%23xE9%3Bcnica%20de%20Reprodu%26%23xE7%3B%26%23xE3%3Bo%20Assistida%20(TRA)%3A%3Cbr%3E%20PUREGON%26%23xAE%3B%20foi%20avaliado%20em%20um%20estudo%20de%20seguran%26%23xE7%3Ba%20e%20efic%26%23xE1%3Bcia%2C%20randomizado%2C%20cego%2C%20com%20grupo%20comparativo%2C%20multic%26%23xEA%3Bntrico%20(estudo%20n%26%23xBA%3B.%2037608)%20em%20981%20mulheres%20inf%26%23xE9%3Brteis%20tratadas%20durante%20um%20ciclo%20para%20fertiliza%26%23xE7%3B%26%23xE3%3Bo%20in%20vitro%20com%20PUREGON%26%23xAE%3B%20ou%20urofolitropina%20ap%26%23xF3%3Bs%20a%20supress%26%23xE3%3Bo%20hipofis%26%23xE1%3Bria%20com%20um%20agonista%20do%20GnRH.%20Os%20resultados%20com%20PUREGON%26%23xAE%3B%20s%26%23xE3%3Bo%20resumidos%20na%20tabela%20a%20seguir.%3Cbr%3E%20PUREGON%26%23xAE%3B%20foi%20tamb%26%23xE9%3Bm%20avaliado%20em%20um%20estudo%20de%20seguran%26%23xE7%3Ba%20e%20efic%26%23xE1%3Bcia%2C%20randomizado%2C%20cego%2C%20grupo%20comparativo%2C%20monoc%26%23xEA%3Bntrico%20(estudo%20n%26%23xBA%3B.%2037604)%20em%2089%20mulheres%20inf%26%23xE9%3Brteis%20tratadas%20com%20PUREGON%26%23xAE%3B%20ou%20menotropinas%20para%20fertiliza%26%23xE7%3B%26%23xE3%3Bo%20in%20vitro%2C%20sem%20supress%26%23xE3%3Bo%20hipofis%26%23xE1%3Bria%20com%20agonista%20do%20GnRH.%3Cbr%3E%20%3Cbr%3E%20Indu%26%23xE7%3B%26%23xE3%3Bo%20da%20ovula%26%23xE7%3B%26%23xE3%3Bo%3A%3Cbr%3E%20Resultados%20de%20um%20estudo%20de%20seguran%26%23xE7%3Ba%20e%20efic%26%23xE1%3Bcia%2C%20randomizado%2C%20cego%2C%20com%20grupo%20comparativo%2C%20multic%26%23xEA%3Bntrico%20(estudo%20n%26%23xBA%3B.%2037609)%20de%20PUREGON%26%23xAE%3B%20em%20172%20mulheres%20com%20anovula%26%23xE7%3B%26%23xE3%3Bo%20cr%26%23xF4%3Bnica%2C%20que%20falharam%20em%20ovular%20e%2Fou%20conceber%20durante%20tratamento%20com%20citrato%20de%20clomifeno%20s%26%23xE3%3Bo%20resumidos%20nas%20duas%20tabelas%20apresentadas%20abaixo.%3Cbr%3E%20%3Cbr%3E%20Homens%3Cbr%3E%20A%20seguran%26%23xE7%3Ba%20e%20efic%26%23xE1%3Bcia%20PUREGON%26%23xAE%3B%20administrado%20por%20inje%26%23xE7%3B%26%23xE3%3Bo%20subcut%26%23xE2%3Bnea%20concomitantemente%20com%20gonadotropina%20cori%26%23xF4%3Bnica%20humana%20(hCG)%20foram%20examinadas%20em%20um%20estudo%20cl%26%23xED%3Bnico%20(estudo%20n%26%23xBA%3B.%2037618)%20para%20indu%26%23xE7%3B%26%23xE3%3Bo%20de%20espermatog%26%23xEA%3Bnese%20em%20homens%20com%20hipogonadismo%20hipogonadotr%26%23xF3%3Bfico.%20O%20estudo%20comparou%20efeitos%20de%20dois%20esquemas%20de%20dosagem%20diferentes%20de%20PUREGON%26%23xAE%3B%2FhCG%20sobre%20par%26%23xE2%3Bmetros%20do%20s%26%23xEA%3Bmen%2C%20concentra%26%23xE7%3B%26%23xF5%3Bes%20s%26%23xE9%3Bricas%20do%20horm%26%23xF4%3Bnio%20fol%26%23xED%3Bculo%20estimulante%20(FSH)%20e%20hCG%2C%20e%20avaliou%20a%20toler%26%23xE2%3Bncia%20local%20da%20via%20de%20administra%26%23xE7%3B%26%23xE3%3Bo%20subcut%26%23xE2%3Bnea%20(SC)%20de%20PUREGON%26%23xAE%3B%20e%20hCG.%20O%20estudo%20multic%26%23xEA%3Bntrico%20envolveu%20uma%20fase%20de%20pr%26%23xE9%3B-tratamento%20de%20dezesseis%20semanas%20com%20hCG%20em%20uma%20dosagem%20de%201.500%20UI%2C%20duas%20vezes%20por%20semana%20para%20normalizar%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20s%26%23xE9%3Bricas%20de%20testosterona.%20Em%20caso%20de%20resposta%20insuficiente%20ap%26%23xF3%3Bs%20oito%20semanas%20de%20tratamento%20(concentra%26%23xE7%3B%26%23xF5%3Bes%20de%20testosterona%20ainda%20abaixo%20da%20varia%26%23xE7%3B%26%23xE3%3Bo%20de%20toler%26%23xE2%3Bncia%20inferior)%2C%20a%20dose%20p%26%23xF4%3Bde%20ser%20aumentada%20para%203.000%20UI%20duas%20vezes%20por%20semana.%20Essa%20fase%20foi%20seguida%20por%20um%20per%26%23xED%3Bodo%20de%20tratamento%20de%2048%20semanas.%20Os%20pacientes%20que%20ainda%20eram%20azoosp%26%23xE9%3Brmicos%20ap%26%23xF3%3Bs%20a%20fase%20de%20pr%26%23xE9%3B-tratamento%20foram%20randomizados%20para%20receber%20225%20UI%20de%20PUREGON%26%23xAE%3B%20juntamente%20com%201.500%20UI%20de%20hCG%20duas%20vezes%20por%20semana%20ou%20150%20UI%20de%20PUREGON%26%23xAE%3B%20tr%26%23xEA%3Bs%20vezes%20por%20semana%20juntamente%20com%201.500%20UI%20de%20hCG%20duas%20vezes%20por%20semana.%20Os%20pacientes%20que%20necessitaram%20de%203.000%20UI%20de%20hCG%20duas%20vezes%20por%20semana%20na%20fase%20de%20pr%26%23xE9%3B-tratamento%20continuaram%20nessa%20dosagem%20durante%20a%20fase%20de%20tratamento.%20A%20m%26%23xE9%3Bdia%20et%26%23xE1%3Bria%20dos%20pacientes%20no%20grupo%20que%20recebeu%20tr%26%23xEA%3Bs%20inje%26%23xE7%3B%26%23xF5%3Bes%20semanais%20de%20PUREGON%26%23xAE%3B%20foi%2030%2C7%20(faixa%20de%2018%20a%2047)%20anos.%20No%20grupo%20que%20recebeu%20duas%20inje%26%23xE7%3B%26%23xF5%3Bes%20semanais%20de%20PUREGON%26%23xAE%3B%2C%20a%20m%26%23xE9%3Bdia%20et%26%23xE1%3Bria%20foi%20de%2030%2C1%20(faixa%20de%2019%20a%2040)%20anos.%20No%20in%26%23xED%3Bcio%20de%20estudo%2C%20os%20volumes%20m%26%23xE9%3Bdios%20de%20test%26%23xED%3Bculo%20esquerdo%20e%20direito%20foram%20de%204%2C61%20%26%23xB1%3B%202%2C94%20mL%20e%204%2C57%20%26%23xB1%3B%203%2C00%20mL%2C%20respectivamente%20no%20grupo%20que%20recebeu%20tr%26%23xEA%3Bs%20inje%26%23xE7%3B%26%23xF5%3Bes%20semanais%20de%20PUREGON%26%23xAE%3B.%20Para%20o%20grupo%20que%20recebeu%20duas%20inje%26%23xE7%3B%26%23xF5%3Bes%20semanais%20de%20PUREGON%26%23xAE%3B%2C%20os%20volumes%20m%26%23xE9%3Bdios%20de%20test%26%23xED%3Bculo%20esquerdo%20e%20direito%20foram%20de%206%2C54%20%26%23xB1%3B%202%2C45%20mL%20e%207%2C21%20%26%23xB1%3B%202%2C94%20mL%2C%20respectivamente%2C%20no%20in%26%23xED%3Bcio%20de%20estudo.%20O%20ponto%20prim%26%23xE1%3Brio%20de%20avalia%26%23xE7%3B%26%23xE3%3Bo%20da%20efic%26%23xE1%3Bcia%20(endpoint)%20foi%20a%20percentagem%20de%20pacientes%20com%20densidade%20esperm%26%23xE1%3Btica%20m%26%23xE9%3Bdia%20de%20%3D%26gt%3B%201%20x%2010%206%2FmL%20em%20suas%20%26%23xFA%3Bltimas%20duas%20avalia%26%23xE7%3B%26%23xF5%3Bes%20do%20tratamento.%20Os%20resultados%20do%20tratamento%20nos%2030%20homens%20inscritos%20na%20fase%20de%20tratamento%20s%26%23xE3%3Bo%20resumidos%20na%20tabela%20a%20seguir.%3Cbr%3E%20%3Cbr%3E%20N%26%23xFA%3Bmero%20de%20homens%20recebendo%20PUREGON%26%23xAE%3B%20que%20atingiram%20densidade%20esperm%26%23xE1%3Btica%20m%26%23xE9%3Bdia%20de%20%3D%26gt%3B%20106%2FmL%20nas%20suas%20%26%23xFA%3Bltimas%20duas%20avalia%26%23xE7%3B%26%23xF5%3Bes%20do%20tratamento%20(estudo%20n%26%23xBA%3B.%2037618)%3Cbr%3E%20%3Cbr%3E%20Em%20pacientes%20que%20apresentaram%20concentra%26%23xE7%3B%26%23xE3%3Bo%20de%20esperma%20de%2C%20no%20m%26%23xED%3Bnimo%2C%20106%20por%20mL%2C%20esta%20foi%20atingida%20em%20um%20tempo%20m%26%23xE9%3Bdio%20de%20165%20dias%20ap%26%23xF3%3Bs%20iniciar%20o%20PUREGON%26%23xAE%3B%2C%20variando%20de%2025%20a%20327%20dias.%20Para%20o%20grupo%20de%20dose%20de%20150%20UI%2C%20o%20tempo%20m%26%23xE9%3Bdio%20para%20atingir%20concentra%26%23xE7%3B%26%23xE3%3Bo%20de%20esperma%20de%2C%20no%20m%26%23xED%3Bnimo%2C%20106%20por%20mL%20foi%20de%20186%20dias%2C%20variando%20de%2025%20a%20327%20dias.%20O%20tempo%20m%26%23xE9%3Bdio%20antes%20desta%20ter%20sido%20atingida%20no%20grupo%20de%20dose%20de%20225%20UI%20foi%20de%20141%20dias%2C%20variando%20de%2043%20a%20204%20dias.%20Nenhum%20dado%20de%20gravidez%20foi%20coletado%20durante%20o%20estudo.%3C%2Fp%3E%0A%3Ch2%3EUsos%20em%20idosos%2C%20crian%26%23xE7%3Bas%20e%20em%20outros%20grupos%20de%20risco%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%20%20%20%20%20%20%20%20%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Famp-ad%3E%0A%3Ch2%3EArmazenagem%3C%2Fh2%3E%0A%3Cp%3ENas%20distribuidoras%20e%20farm%26%23xE1%3Bcias%20PUREGON%26%23xAE%3B%20deve%20ser%20conservado%20sob%20refrigera%26%23xE7%3B%26%23xE3%3Bo%20(entre%202%20e%208%26%23xB0%3BC)%2C%20protegido%20da%20luz.%20N%26%23xE3%3Bo%20congelar.%20Armazenamento%20pelo%20paciente%3A%20h%26%23xE1%3B%20duas%20op%26%23xE7%3B%26%23xF5%3Bes%3A%201)%20armazenar%20o%20produto%20em%20geladeira%20(entre%202%20e%208%26%23xB0%3BC)%2C%20sem%20congelar%3B%202)%20armazenar%20PUREGON%26%23xAE%3B%20em%20ambiente%20com%20temperatura%20m%26%23xE1%3Bxima%20de%2025%26%23xB0%3BC%20por%20um%20per%26%23xED%3Bodo%20de%20at%26%23xE9%3B%203%20meses.%20Anote%20a%20data%20em%20que%20retirar%20o%20produto%20da%20geladeira.%3Cbr%3E%20Mantenha%20a%20carpule%20em%20sua%20embalagem%20externa.%3Cbr%3E%20O%20prazo%20de%20validade%20do%20medicamento%20%26%23xE9%3B%20de%2036%20meses%20a%20partir%20da%20data%20de%20fabrica%26%23xE7%3B%26%23xE3%3Bo.%3Cbr%3E%20%3Cbr%3E%20N%26%23xFA%3Bmero%20de%20lote%20e%20datas%20de%20fabrica%26%23xE7%3B%26%23xE3%3Bo%20e%20validade%3A%20vide%20embalagem.%3Cbr%3E%20N%26%23xE3%3Bo%20use%20medicamento%20com%20o%20prazo%20de%20validade%20vencido.%20Guarde-o%20em%20sua%20embalagem%20original.%3Cbr%3E%20Depois%20que%20a%20camada%20interna%20de%20borracha%20da%20carpule%20for%20perfurada%20com%20uma%20agulha%2C%20o%20produto%20pode%20ser%20utilizado%20no%20m%26%23xE1%3Bximo%20por%2028%20dias.%20Coloque%20a%20data%20do%20primeiro%20uso%20da%20carpule%20no%20cart%26%23xE3%3Bo%20de%20registro%20conforme%20%26%23x93%3BInstru%26%23xE7%3B%26%23xF5%3Bes%20de%20Uso%20de%20PUREGON%20PEN%26%23xAE%3B%26%23x94%3B.%3Cbr%3E%20%3Cbr%3E%20Ap%26%23xF3%3Bs%20aberto%2C%20este%20medicamento%20pode%20ser%20utilizado%20em%20at%26%23xE9%3B%2028%20dias.%3Cbr%3E%20A%20solu%26%23xE7%3B%26%23xE3%3Bo%20de%20PUREGON%26%23xAE%3B%20%26%23xE9%3B%20l%26%23xED%3Bmpida%20e%20incolor.%20Em%20carpules%2C%20se%20destina%20ao%20uso%20com%20uma%20caneta%20injetora%20PUREGON%20PEN%26%23xAE%3B.%20N%26%23xE3%3Bo%20use%20PUREGON%26%23xAE%3B%20se%20voc%26%23xEA%3B%20notar%20que%20a%20solu%26%23xE7%3B%26%23xE3%3Bo%20cont%26%23xE9%3Bm%20part%26%23xED%3Bculas%20ou%20se%20n%26%23xE3%3Bo%20estiver%20l%26%23xED%3Bmpida.%3Cbr%3E%20%3Cbr%3E%20Antes%20de%20usar%2C%20observe%20o%20aspecto%20do%20medicamento.%3Cbr%3E%20Todo%20medicamento%20deve%20ser%20mantido%20fora%20do%20alcance%20das%20crian%26%23xE7%3Bas.%3Cbr%3E%20%3Cbr%3E%20Descarte%20as%20agulhas%20imediatamente%20ap%26%23xF3%3Bs%20a%20inje%26%23xE7%3B%26%23xE3%3Bo.%3Cbr%3E%20Descarte%20as%20carpules%20usadas%20(incluindo%20o%20volume%20restante)%20ap%26%23xF3%3Bs%20a%20%26%23xFA%3Bltima%20inje%26%23xE7%3B%26%23xE3%3Bo%20do%20ciclo%20de%20tratamento.%3Cbr%3E%20PUREGON%26%23xAE%3B%20solu%26%23xE7%3B%26%23xE3%3Bo%20em%20carpules%20n%26%23xE3%3Bo%20pode%20ser%20misturado%20com%20outros%20medicamentos%20nas%20carpules.%20As%20carpules%20vazias%20n%26%23xE3%3Bo%20podem%20ser%20recarregadas.%3Cbr%3E%20Medicamentos%20n%26%23xE3%3Bo%20devem%20ser%20descartados%20no%20lixo%20caseiro%20nem%20na%20%26%23xE1%3Bgua%20usada.%20Essas%20medidas%20auxiliar%26%23xE3%3Bo%20na%20prote%26%23xE7%3B%26%23xE3%3Bo%20do%20meio%20ambiente.%3C%2Fp%3E%0A%3Ch2%3EDizeres%20legais%3C%2Fh2%3E%0A%3Cp%3EMS%201.0171.0081%3Cbr%3E%20Farm.%20Resp.%3A%20Marcos%20C.%20Borgheti%20%26%23x2013%3B%20CRF-SP%20n%26%23xBA%3B%2015.615%3Cbr%3E%20%3Cbr%3E%20Registrado%20e%20importado%20por%3A%3Cbr%3E%20Schering-Plough%20Ind%26%23xFA%3Bstria%20Farmac%26%23xEA%3Butica%20Ltda.%3Cbr%3E%20Rua%20Jo%26%23xE3%3Bo%20Alfredo%2C%20353%20%26%23x96%3B%20S%26%23xE3%3Bo%20Paulo%2FSP%3Cbr%3E%20CNPJ%2003.560.974%2F0001-18%20%26%23x96%3B%20Ind%26%23xFA%3Bstria%20Brasileira%3Cbr%3E%20Central%20de%20Relacionamento%20com%20o%20Cliente%20Schering-Plough%200800-7042590%3Cbr%3E%20centralderelacionamento%40spcorp.com%3Cbr%3E%20%3Cbr%3E%20Fabricado%20por%3A%3Cbr%3E%20Vetter%20Pharma-Fertigung%20GmbH%20%26amp%3B%20Co.%20KG%2C%20Ravensburg%2C%20Alemanha%3Cbr%3E%20%3Cbr%3E%20Embalado%20por%3A%3Cbr%3E%20Merck%20Sharp%20%26amp%3B%20Dohme%20Farmac%26%23xEA%3Butica%20Ltda.%3Cbr%3E%20Rua%2013%20de%20Maio%2C%201.161%20%26%23x96%3B%20Sousas%2C%20Campinas%2FSP%3C%2Fp%3E%0A%3Ch2%3EPUREGON%20%26%23x2013%3B%20Bula%20para%20o%20paciente%3C%2Fh2%3E%0A%3Cp%3E1.%20PARA%20QUE%20ESTE%20MEDICAMENTO%20%26%23xC9%3B%20INDICADO%3F%3Cbr%3E%20PUREGON%26%23xAE%3B%20%26%23xE9%3B%20indicado%20para%20tratar%20a%20infertilidade%20em%20quaisquer%20das%20seguintes%20situa%26%23xE7%3B%26%23xF5%3Bes%3A%3Cbr%3E%20-Em%20mulheres%20que%20n%26%23xE3%3Bo%20est%26%23xE3%3Bo%20ovulando%2C%20PUREGON%26%23xAE%3B%20pode%20ser%20utilizado%20para%20proporcionar%20a%20ovula%26%23xE7%3B%26%23xE3%3Bo%20naquelas%20que%20n%26%23xE3%3Bo%20responderam%20ao%20tratamento%20com%20citrato%20de%20clomifeno.%3Cbr%3E%20-Em%20mulheres%20que%20se%20submeterem%20%26%23xE0%3Bs%20t%26%23xE9%3Bcnicas%20de%20reprodu%26%23xE7%3B%26%23xE3%3Bo%20assistida%2C%20incluindo%20a%20fertiliza%26%23xE7%3B%26%23xE3%3Bo%20in%20vitro%20(FIV)%20e%20outros%20m%26%23xE9%3Btodos%2C%20PUREGON%26%23xAE%3B%20pode%20ser%20utilizado%20para%20desenvolver%20m%26%23xFA%3Bltiplos%20fol%26%23xED%3Bculos.%3Cbr%3E%20-Nos%20homens%20que%20n%26%23xE3%3Bo%20s%26%23xE3%3Bo%20f%26%23xE9%3Brteis%20devido%20a%20uma%20defici%26%23xEA%3Bncia%20hormonal%2C%20PUREGON%26%23xAE%3B%20pode%20ser%20utilizado%20para%20a%20produ%26%23xE7%3B%26%23xE3%3Bo%20do%20esperma.%3Cbr%3E%20%3Cbr%3E%202.%20COMO%20ESTE%20MEDICAMENTO%20FUNCIONA%3F%3Cbr%3E%20PUREGON%26%23xAE%3B%20cont%26%23xE9%3Bm%20o%20horm%26%23xF4%3Bnio%20betafolitropina%2C%20conhecido%20como%20horm%26%23xF4%3Bnio%20fol%26%23xED%3Bculo%20estimulante%20(FSH).%20O%20FSH%20pertence%20ao%20grupo%20das%20gonadotropinas%20que%20desempenha%20um%20papel%20importante%20na%20fertilidade%20e%20reprodu%26%23xE7%3B%26%23xE3%3Bo%20humanas.%20O%20FSH%20na%20mulher%20%26%23xE9%3B%20necess%26%23xE1%3Brio%20para%20o%20crescimento%20e%20desenvolvimento%20dos%20fol%26%23xED%3Bculos%20nos%20ov%26%23xE1%3Brios.%20Os%20fol%26%23xED%3Bculos%20s%26%23xE3%3Bo%20pequenas%20bolsas%20que%20cont%26%23xEA%3Bm%20os%20%26%23xF3%3Bvulos.%3Cbr%3E%20No%20homem%2C%20o%20FSH%20%26%23xE9%3B%20necess%26%23xE1%3Brio%20para%20a%20produ%26%23xE7%3B%26%23xE3%3Bo%20do%20esperma.%3Cbr%3E%20%3Cbr%3E%203.%20QUANDO%20N%26%23xC3%3BO%20DEVO%20USAR%20ESTE%20MEDICAMENTO%3F%20%3Cbr%3E%20Este%20medicamento%20%26%23xE9%3B%20contraindicado%20para%20uso%20por%20pessoas%20com%3A%3Cbr%3E%20%26%23x2212%3B%20Alergia%20(hipersensibilidade)%20%26%23xE0%3B%20betafolitropina%20ou%20a%20quaisquer%20dos%20excipientes.%3Cbr%3E%20%26%23x2212%3BTumores%20de%20ov%26%23xE1%3Brio%2C%20mama%2C%20%26%23xFA%3Btero%2C%20test%26%23xED%3Bculos%20ou%20c%26%23xE9%3Brebro%20(hip%26%23xF3%3Bfise%20ou%20hipot%26%23xE1%3Blamo).%3Cbr%3E%20%26%23x2212%3BSangramento%20vaginal%20intenso%20ou%20irregular%20de%20causa%20desconhecida.%3Cbr%3E%20%26%23x2212%3BInsufici%26%23xEA%3Bncia%20prim%26%23xE1%3Bria%20do%20ov%26%23xE1%3Brio.%3Cbr%3E%20%26%23x2212%3BCistos%20ovarianos%20ou%20ov%26%23xE1%3Brios%20aumentados%2C%20n%26%23xE3%3Bo%20relacionados%20com%20s%26%23xED%3Bndrome%20de%20ov%26%23xE1%3Brios%20polic%26%23xED%3Bsticos.%3Cbr%3E%20%26%23x2212%3BMalforma%26%23xE7%3B%26%23xF5%3Bes%20dos%20%26%23xF3%3Brg%26%23xE3%3Bos%20reprodutivos%20incompat%26%23xED%3Bveis%20com%20uma%20gravidez%20normal.%3Cbr%3E%20%26%23x2212%3BMiomas%20uterinos%20incompat%26%23xED%3Bveis%20com%20uma%20gravidez%20normal.%3Cbr%3E%20%26%23x2212%3BInsufici%26%23xEA%3Bncia%20prim%26%23xE1%3Bria%20dos%20test%26%23xED%3Bculos.%3Cbr%3E%20%3Cbr%3E%20Este%20medicamento%20%26%23xE9%3B%20contraindicado%20para%20uso%20por%20mulheres%20gr%26%23xE1%3Bvidas%20ou%20que%20suspeitam%20que%20possam%20estar.%3Cbr%3E%20%3Cbr%3E%204.%20O%20QUE%20DEVO%20SABER%20ANTES%20DE%20USAR%20ESTE%20MEDICAMENTO%3F%3Cbr%3E%20Informe%20ao%20seu%20m%26%23xE9%3Bdico%20se%20voc%26%23xEA%3B%3A%3Cbr%3E%20-j%26%23xE1%3B%20apresentou%20rea%26%23xE7%3B%26%23xE3%3Bo%20al%26%23xE9%3Brgica%20%26%23xE0%3B%20neomicina%20e%2Fou%20%26%23xE0%3B%20estreptomicina%20(antibi%26%23xF3%3Bticos).%3Cbr%3E%20-apresenta%20gl%26%23xE2%3Bndula%20pituit%26%23xE1%3Bria%20descontrolada%20ou%20problemas%20no%20hipot%26%23xE1%3Blamo.%3Cbr%3E%20-apresenta%20hipoatividade%20da%20gl%26%23xE2%3Bndula%20tire%26%23xF3%3Bide%20(hipotireoidismo).%3Cbr%3E%20-apresenta%20gl%26%23xE2%3Bndulas%20adrenais%20que%20n%26%23xE3%3Bo%20funcionam%20apropriadamente%20(insufici%26%23xEA%3Bncia%20adrenocortical).%3Cbr%3E%20-apresenta%20alta%20concentra%26%23xE7%3B%26%23xE3%3Bo%20de%20prolactina%20no%20sangue%20(hiperprolactinemia).%3Cbr%3E%20-apresenta%20qualquer%20outra%20condi%26%23xE7%3B%26%23xE3%3Bo%20m%26%23xE9%3Bdica%20(por%20exemplo%20diabetes%2C%20doen%26%23xE7%3Ba%20card%26%23xED%3Baca%20ou%20qualquer%20outra%20doen%26%23xE7%3Ba%20de%20longa%20data).%3Cbr%3E%20%3Cbr%3E%20Em%20mulheres%3A%3Cbr%3E%20%26%23xC9%3B%20muito%20importante%20a%20supervis%26%23xE3%3Bo%20m%26%23xE9%3Bdica%20rigorosa.%20Geralmente%2C%20em%20intervalos%20regulares%2C%20s%26%23xE3%3Bo%20realizadas%20ultrassonografias%20dos%20ov%26%23xE1%3Brios.%20Seu%20m%26%23xE9%3Bdico%20poder%26%23xE1%3B%20checar%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20de%20horm%26%23xF4%3Bnio%20no%20sangue.%20Os%20resultados%20desses%20exames%20permitem%20que%20seu%20m%26%23xE9%3Bdico%20escolha%20a%20dose%20correta%20de%20PUREGON%26%23xAE%3B%20a%20ser%20administrada%20durante%20todo%20o%20tratamento.%20Isso%20%26%23xE9%3B%20muito%20importante%2C%20pois%20doses%20muito%20elevadas%20de%20FSH%20podem%20ocasionar%20complica%26%23xE7%3B%26%23xF5%3Bes%20raras%2C%20mas%20graves%2C%20nas%20quais%20os%20ov%26%23xE1%3Brios%20s%26%23xE3%3Bo%20excessivamente%20estimulados%20e%20os%20fol%26%23xED%3Bculos%20em%20crescimento%20tornam-se%20maiores%20que%20os%20normais.%20Esta%20condi%26%23xE7%3B%26%23xE3%3Bo%20m%26%23xE9%3Bdica%20grave%20%26%23xE9%3B%20chamada%20de%20s%26%23xED%3Bndrome%20de%20hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20(SHEO).%20Em%20casos%20raros%2C%20a%20SHEO%20grave%20pode%20representar%20risco%20%26%23xE0%3B%20vida.%20SHEO%20causa%20ac%26%23xFA%3Bmulo%20repentino%20de%20flu%26%23xED%3Bdo%20na%20%26%23xE1%3Brea%20do%20est%26%23xF4%3Bmago%20e%20t%26%23xF3%3Brax%20e%20pode%20causar%20a%20forma%26%23xE7%3B%26%23xE3%3Bo%20de%20co%26%23xE1%3Bgulos%20de%20sangue.%20Procure%20seu%20m%26%23xE9%3Bdico%20imediatamente%20se%20voc%26%23xEA%3B%20notar%20incha%26%23xE7%3Bo%20abdominal%2C%20dor%20na%20%26%23xE1%3Brea%20do%20est%26%23xF4%3Bmago%20(abdome)%2C%20mal-estar%20geral%20(n%26%23xE1%3Busea)%2C%20v%26%23xF4%3Bmito%2C%20ganho%20de%20peso%20repentino%20devido%20ao%20ac%26%23xFA%3Bmulo%20de%20flu%26%23xED%3Bdo%2C%20diarreia%2C%20diminui%26%23xE7%3B%26%23xE3%3Bo%20da%20produ%26%23xE7%3B%26%23xE3%3Bo%20de%20urina%20ou%20dificuldade%20para%20respirar%20(ver%20tamb%26%23xE9%3Bm%20%26%23x93%3B8.%20QUAIS%20OS%20MALES%20QUE%20ESTE%20MEDICAMENTO%20PODE%20ME%20CAUSAR%3F%26%23x94%3B).%20A%20monitora%26%23xE7%3B%26%23xE3%3Bo%20regular%20da%20resposta%20ao%20tratamento%20com%20FSH%20auxilia%20o%20seu%20m%26%23xE9%3Bdico%20a%20prevenir%20a%20hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20ovariana.%20Portanto%2C%20contate-o%20imediatamente%20se%20apresentar%20dor%20estomacal%20significativa%2C%20mesmo%20que%20ela%20ocorra%20alguns%20dias%20depois%20que%20a%20%26%23xFA%3Bltima%20inje%26%23xE7%3B%26%23xE3%3Bo%20tiver%20sido%20administrada.%3Cbr%3E%20Tor%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20tem%20ocorrido%20ap%26%23xF3%3Bs%20o%20tratamento%20com%20gonadotropinas%2C%20incluindo%20PUREGON%26%23xAE%3B.%20Tor%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20%26%23xE9%3B%20uma%20tor%26%23xE7%3B%26%23xE3%3Bo%20do%20ov%26%23xE1%3Brio%20que%20pode%20reduzir%20o%20fluxo%20sangu%26%23xED%3Bneo%20para%20o%20ov%26%23xE1%3Brio%20at%26%23xE9%3B%20interromp%26%23xEA%3B-lo.%3Cbr%3E%20Antes%20de%20usar%20este%20medicamento%2C%20%26%23xE9%3B%20importante%20informar%20seu%20m%26%23xE9%3Bdico%20se%20voc%26%23xEA%3B%3A%3Cbr%3E%20-j%26%23xE1%3B%20teve%20s%26%23xED%3Bndrome%20de%20hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20(SHEO).%3Cbr%3E%20-est%26%23xE1%3B%20gr%26%23xE1%3Bvida%20ou%20suspeita%20que%20possa%20estar%20gr%26%23xE1%3Bvida.%3Cbr%3E%20-j%26%23xE1%3B%20fez%20cirurgia%20do%20est%26%23xF4%3Bmago%20(abdominal).%3Cbr%3E%20-j%26%23xE1%3B%20teve%20tor%26%23xE7%3B%26%23xE3%3Bo%20no%20ov%26%23xE1%3Brio.%3Cbr%3E%20-teve%20ou%20t%26%23xEA%3Bm%20cistos%20em%20um%20dos%20seus%20ov%26%23xE1%3Brios%20ou%20nos%20dois.%3Cbr%3E%20O%20tratamento%20com%20PUREGON%26%23xAE%3B%20(assim%20como%20a%20pr%26%23xF3%3Bpria%20gravidez)%20pode%20aumentar%20o%20risco%20de%20trombose%2C%20que%20%26%23xE9%3B%20a%20forma%26%23xE7%3B%26%23xE3%3Bo%20de%20co%26%23xE1%3Bgulo%20em%20um%20vaso%20sangu%26%23xED%3Bneo.%3Cbr%3E%20Co%26%23xE1%3Bgulo%20de%20sangue%20pode%20levar%20a%20uma%20condi%26%23xE7%3B%26%23xE3%3Bo%20m%26%23xE9%3Bdica%20grave%2C%20como%3A%3Cbr%3E%20-bloqueio%20de%20seus%20pulm%26%23xF5%3Bes%20(embolia%20pulmonar).%3Cbr%3E%20-derrame.%3Cbr%3E%20-ataque%20card%26%23xED%3Baco.%3Cbr%3E%20-problemas%20de%20vaso%20sangu%26%23xED%3Bneo%20(tromboflebite).%3Cbr%3E%20-uma%20falta%20de%20fluxo%20de%20sangue%20(trombose%20de%20veia%20profunda)%20que%20pode%20resultar%20em%20uma%20perda%20de%20seu%20bra%26%23xE7%3Bo%20ou%20perna.%3Cbr%3E%20%3Cbr%3E%20Converse%20com%20o%20seu%20m%26%23xE9%3Bdico%20antes%20de%20iniciar%20o%20tratamento%2C%20especialmente%20se%3A%3Cbr%3E%20-souber%20que%20apresenta%20maior%20risco%20de%20trombose.%3Cbr%3E%20-voc%26%23xEA%3B%20ou%20algum%20membro%20de%20sua%20fam%26%23xED%3Blia%20tem%20ou%20teve%20trombose.%3Cbr%3E%20-estiver%20com%20o%20peso%20muito%20acima%20do%20normal.%3Cbr%3E%20Ap%26%23xF3%3Bs%20tratamento%20com%20prepara%26%23xE7%3B%26%23xF5%3Bes%20de%20gonadotropina%2C%20existe%20uma%20chance%20aumentada%20de%20gesta%26%23xE7%3B%26%23xF5%3Bes%20m%26%23xFA%3Bltiplas%2C%20mesmo%20quando%20apenas%20um%20embri%26%23xE3%3Bo%20%26%23xE9%3B%20transferido%20para%20o%20%26%23xFA%3Btero.%20As%20gesta%26%23xE7%3B%26%23xF5%3Bes%20m%26%23xFA%3Bltiplas%20implicam%20em%20um%20aumento%20do%20risco%20para%20a%20sa%26%23xFA%3Bde%20da%20m%26%23xE3%3Be%20e%20dos%20seus%20beb%26%23xEA%3Bs%20no%20momento%20do%20parto.%20Al%26%23xE9%3Bm%20disso%2C%20gesta%26%23xE7%3B%26%23xF5%3Bes%20m%26%23xFA%3Bltiplas%20e%20caracter%26%23xED%3Bsticas%20dos%20pacientes%20submetidos%20a%20tratamento%20de%20fertilidade%20(por%20exemplo%2C%20idade%20da%20m%26%23xE3%3Be%2C%20caracter%26%23xED%3Bsticas%20do%20esperma%2C%20forma%26%23xE7%3B%26%23xE3%3Bo%20gen%26%23xE9%3Btica%20de%20ambos%20os%20pais)%20podem%20estar%20associadas%20com%20um%20aumento%20no%20risco%20de%20defeitos%20de%20nascimento.%3Cbr%3E%20H%26%23xE1%3B%20um%20pequeno%20aumento%20de%20risco%20de%20uma%20gravidez%20fora%20do%20%26%23xFA%3Btero%20(gravidez%20ect%26%23xF3%3Bpica).%20Portanto%2C%20seu%20m%26%23xE9%3Bdico%20dever%26%23xE1%3B%20realizar%20um%20exame%20ultrassonogr%26%23xE1%3Bfico%20precoce%20para%20excluir%20a%20possibilidade%20de%20gravidez%20fora%20do%20%26%23xFA%3Btero.%3Cbr%3E%20H%26%23xE1%3B%20relatos%20de%20tumores%20de%20ov%26%23xE1%3Brio%20e%20de%20outros%20do%20sistema%20reprodutor%20em%20mulheres%20que%20fizeram%20tratamento%20para%20infertilidade.%20N%26%23xE3%3Bo%20%26%23xE9%3B%20conhecido%20se%20o%20tratamento%20com%20medicamentos%20para%20fertilidade%20aumenta%20o%20risco%20desses%20tumores%20em%20mulheres%20inf%26%23xE9%3Brteis.%3Cbr%3E%20Outras%20condi%26%23xE7%3B%26%23xF5%3Bes%20m%26%23xE9%3Bdicas%3A%3Cbr%3E%20Al%26%23xE9%3Bm%20disso%2C%20antes%20de%20iniciar%20o%20uso%20deste%20medicamento%2C%20informe%20o%20seu%20m%26%23xE9%3Bdico%20se%20algum%20m%26%23xE9%3Bdico%20disse%20que%20a%20gravidez%20poderia%20ser%20perigosa%20para%20voc%26%23xEA%3B.%3Cbr%3E%20%3Cbr%3E%20Em%20homens%3A%3Cbr%3E%20Concentra%26%23xE7%3B%26%23xF5%3Bes%20elevadas%20de%20FSH%20no%20sangue%20s%26%23xE3%3Bo%20indicativas%20de%20dano%20testicular.%20PUREGON%26%23xAE%3B%20geralmente%20n%26%23xE3%3Bo%20%26%23xE9%3B%20eficaz%20nesses%20casos.%20Para%20monitorar%20o%20tratamento%2C%20o%20seu%20m%26%23xE9%3Bdico%20pode%20solicitar%20uma%20an%26%23xE1%3Blise%20do%20s%26%23xEA%3Bmen%20cerca%20de%204%20a%206%20meses%20ap%26%23xF3%3Bs%20o%20in%26%23xED%3Bcio%20do%20tratamento.%3Cbr%3E%20%3Cbr%3E%20Gravidez%20e%20lacta%26%23xE7%3B%26%23xE3%3Bo%3Cbr%3E%20Pe%26%23xE7%3Ba%20orienta%26%23xE7%3B%26%23xE3%3Bo%20ao%20seu%20m%26%23xE9%3Bdico%20ou%20farmac%26%23xEA%3Butico%20antes%20de%20usar%20qualquer%20medicamento.%20Voc%26%23xEA%3B%20n%26%23xE3%3Bo%20deve%20usar%20PUREGON%26%23xAE%3B%20se%20estiver%20gr%26%23xE1%3Bvida%20ou%20suspeitar%20que%20possa%20estar%20gr%26%23xE1%3Bvida.%3Cbr%3E%20Se%20estiver%20amamentando%2C%20informe%20seu%20m%26%23xE9%3Bdico%20antes%20de%20usar%20PUREGON%26%23xAE%3B.%3Cbr%3E%20%3Cbr%3E%20Efeitos%20sobre%20a%20habilidade%20de%20dirigir%20e%20operar%20m%26%23xE1%3Bquinas%3Cbr%3E%20N%26%23xE3%3Bo%20foram%20observados%20efeitos%20sobre%20a%20habilidade%20de%20dirigir%20ve%26%23xED%3Bculos%20e%20operar%20m%26%23xE1%3Bquinas.%3Cbr%3E%20%3Cbr%3E%20Aten%26%23xE7%3B%26%23xE3%3Bo%20diab%26%23xE9%3Bticos%3A%20cont%26%23xE9%3Bm%20a%26%23xE7%3B%26%23xFA%3Bcar.%3Cbr%3E%20Este%20medicamento%20pode%20causar%20doping.%3Cbr%3E%20%3Cbr%3E%20Intera%26%23xE7%3B%26%23xF5%3Bes%20medicamentosas%3Cbr%3E%20Se%20PUREGON%26%23xAE%3B%20for%20utilizado%20em%20combina%26%23xE7%3B%26%23xE3%3Bo%20com%20citrato%20de%20clomifeno%20pode%20haver%20uma%20resposta%20folicular%20aumentada.%20Se%20for%20administrado%20um%20agonista%20do%20GnRH%20(medicamento%20utilizado%20para%20prevenir%20ovula%26%23xE7%3B%26%23xE3%3Bo%20antecipada)%20poder%26%23xE3%3Bo%20ser%20necess%26%23xE1%3Brias%20doses%20maiores%20de%20PUREGON%26%23xAE%3B%20para%20produzir%20resposta%20adequada.%3Cbr%3E%20Informe%20ao%20seu%20m%26%23xE9%3Bdico%20ou%20farmac%26%23xEA%3Butico%20se%20estiver%20usando%20medicamentos%2C%20incluindo%20os%20que%20n%26%23xE3%3Bo%20precisam%20de%20receita%20m%26%23xE9%3Bdica%20para%20serem%20adquiridos.%3Cbr%3E%20%3Cbr%3E%20Informe%20ao%20seu%20m%26%23xE9%3Bdico%20ou%20cirurgi%26%23xE3%3Bo-dentista%20se%20voc%26%23xEA%3B%20est%26%23xE1%3B%20fazendo%20uso%20de%20algum%20outro%20medicamento.%20N%26%23xE3%3Bo%20use%20medicamento%20sem%20o%20conhecimento%20do%20seu%20m%26%23xE9%3Bdico.%20Pode%20ser%20perigoso%20para%20a%20sua%20sa%26%23xFA%3Bde.%3Cbr%3E%20%3Cbr%3E%205.%20ONDE%2C%20COMO%20E%20POR%20QUANTO%20TEMPO%20POSSO%20GUARDAR%20ESTE%20MEDICAMENTO%3F%3Cbr%3E%20Nas%20distribuidoras%20e%20farm%26%23xE1%3Bcias%20PUREGON%26%23xAE%3B%20deve%20ser%20conservado%20sob%20refrigera%26%23xE7%3B%26%23xE3%3Bo%20(entre%202%20e%208%26%23xB0%3BC)%2C%20protegido%20da%20luz.%20N%26%23xE3%3Bo%20congelar.%20Armazenamento%20pelo%20paciente%3A%20h%26%23xE1%3B%20duas%20op%26%23xE7%3B%26%23xF5%3Bes%3A%201)%20armazenar%20o%20produto%20em%20geladeira%20(entre%202%20e%208%26%23xB0%3BC)%2C%20sem%20congelar%3B%202)%20armazenar%20PUREGON%26%23xAE%3B%20em%20ambiente%20com%20temperatura%20m%26%23xE1%3Bxima%20de%2025%26%23xB0%3BC%20por%20um%20per%26%23xED%3Bodo%20de%20at%26%23xE9%3B%203%20meses.%20Anote%20a%20data%20em%20que%20retirar%20o%20produto%20da%20geladeira.%3Cbr%3E%20Mantenha%20a%20carpule%20em%20sua%20embalagem%20externa.%3Cbr%3E%20%3Cbr%3E%20N%26%23xFA%3Bmero%20de%20lote%20e%20datas%20de%20fabrica%26%23xE7%3B%26%23xE3%3Bo%20e%20validade%3A%20vide%20embalagem.%3Cbr%3E%20N%26%23xE3%3Bo%20use%20medicamento%20com%20o%20prazo%20de%20validade%20vencido.%20Guarde-o%20em%20sua%20embalagem%20original.%3Cbr%3E%20%3Cbr%3E%20Depois%20que%20a%20camada%20interna%20de%20borracha%20da%20carpule%20for%20perfurada%20com%20uma%20agulha%2C%20o%20produto%20pode%20ser%20utilizado%20no%20m%26%23xE1%3Bximo%20por%2028%20dias.%20Coloque%20a%20data%20do%20primeiro%20uso%20da%20carpule%20no%20cart%26%23xE3%3Bo%20de%20registro%20conforme%20%26%23x93%3BInstru%26%23xE7%3B%26%23xF5%3Bes%20de%20Uso%20de%20PUREGON%20PEN%26%23xAE%3B%26%23x94%3B.%3Cbr%3E%20Ap%26%23xF3%3Bs%20aberto%2C%20este%20medicamento%20pode%20ser%20utilizado%20em%20at%26%23xE9%3B%2028%20dias.%3Cbr%3E%20A%20solu%26%23xE7%3B%26%23xE3%3Bo%20de%20PUREGON%26%23xAE%3B%20%26%23xE9%3B%20l%26%23xED%3Bmpida%20e%20incolor.%20Em%20carpules%2C%20destina-se%20ao%20uso%20com%20uma%20caneta%20injetora%20PUREGON%20PEN%26%23xAE%3B.%3Cbr%3E%20N%26%23xE3%3Bo%20use%20PUREGON%26%23xAE%3B%20se%20voc%26%23xEA%3B%20notar%20que%20a%20solu%26%23xE7%3B%26%23xE3%3Bo%20cont%26%23xE9%3Bm%20part%26%23xED%3Bculas%20ou%20se%20n%26%23xE3%3Bo%20estiver%20l%26%23xED%3Bmpida.%3Cbr%3E%20%3Cbr%3E%20Antes%20de%20usar%2C%20observe%20o%20aspecto%20do%20medicamento.%20Caso%20ele%20esteja%20no%20prazo%20de%20validade%20e%20voc%26%23xEA%3B%20observe%20alguma%20mudan%26%23xE7%3Ba%20no%20aspecto%2C%20consulte%20o%20farmac%26%23xEA%3Butico%20para%20saber%20se%20poder%26%23xE1%3B%20utiliz%26%23xE1%3B-lo.%3Cbr%3E%20%3Cbr%3E%20Todo%20medicamento%20deve%20ser%20mantido%20fora%20do%20alcance%20das%20crian%26%23xE7%3Bas.%3Cbr%3E%20Descarte%20as%20agulhas%20imediatamente%20ap%26%23xF3%3Bs%20a%20inje%26%23xE7%3B%26%23xE3%3Bo.%3Cbr%3E%20Descarte%20as%20carpules%20usadas%20(incluindo%20o%20volume%20restante)%20ap%26%23xF3%3Bs%20a%20%26%23xFA%3Bltima%20inje%26%23xE7%3B%26%23xE3%3Bo%20do%20ciclo%20de%20tratamento.%20PUREGON%26%23xAE%3B%20solu%26%23xE7%3B%26%23xE3%3Bo%20em%20carpules%20n%26%23xE3%3Bo%20pode%20ser%20misturado%20com%20outros%20medicamentos%20nas%20carpules.%20As%20carpules%20vazias%20n%26%23xE3%3Bo%20podem%20ser%20recarregadas.%3Cbr%3E%20Medicamentos%20n%26%23xE3%3Bo%20devem%20ser%20descartados%20no%20lixo%20caseiro%20nem%20na%20%26%23xE1%3Bgua%20usada.%20Pergunte%20ao%20seu%20farmac%26%23xEA%3Butico%20como%20jogar%20fora%20medicamentos%20que%20n%26%23xE3%3Bo%20podem%20mais%20ser%20usados.%20Essas%20medidas%20auxiliar%26%23xE3%3Bo%20na%20prote%26%23xE7%3B%26%23xE3%3Bo%20do%20meio%20ambiente.%3Cbr%3E%20%3Cbr%3E%206.%20COMO%20DEVO%20USAR%20ESTE%20MEDICAMENTO%3F%3Cbr%3E%20As%20inje%26%23xE7%3B%26%23xF5%3Bes%20iniciais%20de%20PUREGON%26%23xAE%3B%20devem%20ser%20aplicadas%20apenas%20sob%20supervis%26%23xE3%3Bo%20m%26%23xE9%3Bdica.%3Cbr%3E%20PUREGON%26%23xAE%3B%20solu%26%23xE7%3B%26%23xE3%3Bo%20injet%26%23xE1%3Bvel%20em%20carpules%20foi%20desenvolvido%20para%20ser%20utilizado%20em%20conjunto%20com%20a%20caneta%20injetora%20PUREGON%20PEN%26%23xAE%3B.%20Siga%20cuidadosamente%20as%20instru%26%23xE7%3B%26%23xF5%3Bes%20de%20uso%20que%20acompanham%20PUREGON%20PEN%26%23xAE%3B.%3Cbr%3E%20N%26%23xE3%3Bo%20utilize%20a%20carpule%20se%20a%20solu%26%23xE7%3B%26%23xE3%3Bo%20contiver%20part%26%23xED%3Bculas%20ou%20n%26%23xE3%3Bo%20estiver%20l%26%23xED%3Bmpida.%3Cbr%3E%20Utilizando%20a%20caneta%20PUREGON%20PEN%26%23xAE%3B%2C%20as%20inje%26%23xE7%3B%26%23xF5%3Bes%20sob%20a%20pele%20(na%20parede%20abdominal%2C%20por%20exemplo)%20podem%20ser%20aplicadas%20por%20voc%26%23xEA%3B%20mesma(o)%20ou%20seu(sua)%20parceiro(a).%20Seu%20m%26%23xE9%3Bdico%20a(o)%20orientar%26%23xE1%3B%20quando%20isso%20puder%20ser%20feito.%20Quando%20as%20instru%26%23xE7%3B%26%23xF5%3Bes%20forem%20seguidas%20corretamente%2C%20PUREGON%26%23xAE%3B%20poder%26%23xE1%3B%20ser%20administrado%20apropriadamente%20e%20com%20desconforto%20m%26%23xED%3Bnimo.%3Cbr%3E%20%3Cbr%3E%20Posologia%3A%3Cbr%3E%20Sempre%20utilize%20PUREGON%26%23xAE%3B%20exatamente%20conforme%20instru%26%23xED%3Bdo%20pelo%20seu%20m%26%23xE9%3Bdico.%20Caso%20voc%26%23xEA%3B%20n%26%23xE3%3Bo%20esteja%20seguro%2C%20verifique%20com%20o%20seu%20m%26%23xE9%3Bdico%20ou%20farmac%26%23xEA%3Butico.%3Cbr%3E%20%3Cbr%3E%20Doses%20para%20mulheres%3Cbr%3E%20O%20seu%20m%26%23xE9%3Bdico%20decidir%26%23xE1%3B%20sobre%20a%20dose%20de%20PUREGON%26%23xAE%3B%20que%20deve%20ser%20utilizada%20no%20seu%20caso%2C%20que%20poder%26%23xE1%3B%20ser%20ajustada%20%26%23xE0%3B%20medida%20que%20o%20tratamento%20prosseguir.%20Maiores%20detalhes%20sobre%20o%20esquema%20de%20tratamento%20s%26%23xE3%3Bo%20fornecidos%20a%20seguir.%20H%26%23xE1%3B%20grandes%20diferen%26%23xE7%3Bas%20entre%20as%20mulheres%20com%20rela%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE0%3B%20resposta%20dos%20ov%26%23xE1%3Brios%20ao%20FSH%2C%20que%20tornam%20imposs%26%23xED%3Bvel%20estabelecer%20um%20esquema%20de%20doses%20padronizado%20que%20possa%20ser%20utilizado%20em%20todas%20as%20pacientes.%20Para%20encontrar%20a%20dose%20correta%2C%20o%20crescimento%20do%20fol%26%23xED%3Bculo%20%26%23xE9%3B%20verificado%20pela%20ultrassonografia%20e%20dosagem%20da%20quantidade%20de%20estradiol%20(horm%26%23xF4%3Bnio%20sexual%20feminino)%20no%20sangue.%3Cbr%3E%20%3Cbr%3E%20-Mulheres%20que%20n%26%23xE3%3Bo%20est%26%23xE3%3Bo%20ovulando%3Cbr%3E%20Inicialmente%20a%20dose%20%26%23xE9%3B%20definida%20pelo%20seu%20m%26%23xE9%3Bdico%20e%20ser%26%23xE1%3B%20mantida%20por%2C%20pelo%20menos%2C%207%20dias.%20Se%20n%26%23xE3%3Bo%20houver%20resposta%20ovariana%2C%20a%20dose%20di%26%23xE1%3Bria%20ser%26%23xE1%3B%20aumentada%20gradativamente%2C%20at%26%23xE9%3B%20que%20o%20crescimento%20do%20fol%26%23xED%3Bculo%20e%2Fou%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20de%20estradiol%20indiquem%20que%20h%26%23xE1%3B%20resposta%20adequada.%20A%20dose%20di%26%23xE1%3Bria%2C%20ent%26%23xE3%3Bo%2C%20%26%23xE9%3B%20mantida%20at%26%23xE9%3B%20que%20um%20fol%26%23xED%3Bculo%20de%20tamanho%20adequado%20esteja%20presente.%20Geralmente%2C%207%20a%2014%20dias%20de%20tratamento%20s%26%23xE3%3Bo%20suficientes.%20A%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20PUREGON%26%23xAE%3B%20%26%23xE9%3B%2C%20ent%26%23xE3%3Bo%2C%20interrompida%20e%20a%20ovula%26%23xE7%3B%26%23xE3%3Bo%20pode%20ser%20induzida%20pela%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20gonadotropina%20cori%26%23xF4%3Bnica%20humana%20(hCG).%3Cbr%3E%20%3Cbr%3E%20-Programas%20de%20reprodu%26%23xE7%3B%26%23xE3%3Bo%20assistida%20%5Bpor%20exemplo%2C%20fertiliza%26%23xE7%3B%26%23xE3%3Bo%20in%20vitro%20(FIV)%5D%3Cbr%3E%20A%20dose%20inicial%20%26%23xE9%3B%20definida%20pelo%20seu%20m%26%23xE9%3Bdico%20e%20ser%26%23xE1%3B%20mantida%20durante%20pelo%20menos%20os%20quatro%20primeiros%20dias.%20Depois%20disso%2C%20a%20dose%20pode%20ser%20ajustada%20para%20a%20paciente%20individualmente%2C%20com%20base%20em%20sua%20resposta%20ovariana.%20Quando%20um%20n%26%23xFA%3Bmero%20suficiente%20de%20fol%26%23xED%3Bculos%20de%20tamanho%20adequado%20estiver%20presente%2C%20a%20fase%20final%20de%20matura%26%23xE7%3B%26%23xE3%3Bo%20dos%20fol%26%23xED%3Bculos%20%26%23xE9%3B%20induzida%20pela%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20hCG.%20A%20retirada%20do%20ovo%20(o%26%23xF3%3Bcito)%20%26%23xE9%3B%20realizada%20depois%20de%2034%20a%2035%20horas.%3Cbr%3E%20%3Cbr%3E%20Doses%20para%20homens%3Cbr%3E%20PUREGON%26%23xAE%3B%20%26%23xE9%3B%20geralmente%20prescrito%20na%20dose%20de%20450%20UI%2Fsemana%2C%20mais%20frequentemente%20em%203%20administra%26%23xE7%3B%26%23xF5%3Bes%20de%20150%20UI%2C%20em%20combina%26%23xE7%3B%26%23xE3%3Bo%20com%20outro%20horm%26%23xF4%3Bnio%20(hCG)%20por%20pelo%20menos%203%20a%204%20meses.%20Se%20n%26%23xE3%3Bo%20houver%20resposta%20ap%26%23xF3%3Bs%20esse%20per%26%23xED%3Bodo%2C%20o%20tratamento%20pode%20ser%20prolongado%20por%20pelo%20menos%2018%20meses.%3Cbr%3E%20%3Cbr%3E%20Siga%20a%20orienta%26%23xE7%3B%26%23xE3%3Bo%20de%20seu%20m%26%23xE9%3Bdico%2C%20respeitando%20sempre%20os%20hor%26%23xE1%3Brios%2C%20as%20doses%20e%20a%20dura%26%23xE7%3B%26%23xE3%3Bo%20do%20tratamento.%20N%26%23xE3%3Bo%20interrompa%20o%20tratamento%20sem%20o%20conhecimento%20do%20seu%20m%26%23xE9%3Bdico.%3Cbr%3E%20%3Cbr%3E%207.%20O%20QUE%20DEVO%20FAZER%20QUANDO%20EU%20ME%20ESQUECER%20DE%20USAR%20ESTE%20MEDICAMENTO%3F%3Cbr%3E%20Se%20voc%26%23xEA%3B%20se%20esquecer%20de%20administrar%20PUREGON%26%23xAE%3B%2C%20n%26%23xE3%3Bo%20use%20uma%20dose%20dupla%20para%20compensar%20a%20dose%20esquecida.%20Informe%20ao%20seu%20m%26%23xE9%3Bdico%20que%20voc%26%23xEA%3B%20se%20esqueceu%20de%20tomar%20a%20inje%26%23xE7%3B%26%23xE3%3Bo.%3Cbr%3E%20%3Cbr%3E%20Em%20caso%20de%20d%26%23xFA%3Bvidas%2C%20procure%20orienta%26%23xE7%3B%26%23xE3%3Bo%20do%20farmac%26%23xEA%3Butico%20ou%20de%20seu%20m%26%23xE9%3Bdico%2C%20ou%20cirurgi%26%23xE3%3Bo-dentista.%3Cbr%3E%20%3Cbr%3E%208.%20QUAIS%20OS%20MALES%20QUE%20ESTE%20MEDICAMENTO%20PODE%20ME%20CAUSAR%3F%3Cbr%3E%20Assim%20como%20todos%20os%20medicamentos%2C%20PUREGON%26%23xAE%3B%20pode%20causar%20rea%26%23xE7%3B%26%23xF5%3Bes%20indesej%26%23xE1%3Bveis%2C%20embora%20nem%20todas%20as%20pessoas%20as%20apresentem.%3Cbr%3E%20%3Cbr%3E%20Em%20mulheres%3A%3Cbr%3E%20Uma%20complica%26%23xE7%3B%26%23xE3%3Bo%20decorrente%20do%20tratamento%20com%20FSH%20%26%23xE9%3B%20a%20hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20indesejada%20dos%20ov%26%23xE1%3Brios.%20A%20hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20pode%20desenvolver%20uma%20condi%26%23xE7%3B%26%23xE3%3Bo%20m%26%23xE9%3Bdica%20chamada%20S%26%23xED%3Bndrome%20de%20Hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20Ovariana%20(SHEO)%2C%20que%20pode%20ser%20um%20problema%20m%26%23xE9%3Bdico%20grave.%20O%20risco%20pode%20ser%20reduzido%20pela%20monitora%26%23xE7%3B%26%23xE3%3Bo%20cuidadosa%20do%20desenvolvimento%20dos%20fol%26%23xED%3Bculos%20durante%20o%20tratamento.%20Seu%20m%26%23xE9%3Bdico%20ir%26%23xE1%3B%20fazer%20uma%20ultrassonografia%20de%20seus%20ov%26%23xE1%3Brios%20para%20monitorar%20cuidadosamente%20o%20n%26%23xFA%3Bmero%20de%20fol%26%23xED%3Bculos%20maduros.%20Ele%20poder%26%23xE1%3B%20tamb%26%23xE9%3Bm%20checar%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20de%20horm%26%23xF4%3Bnio%20no%20sangue.%20Os%20primeiros%20sintomas%20de%20hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20podem%20ser%20notados%20por%20dor%20no%20est%26%23xF4%3Bmago%20(abdome)%2C%20mal-estar%20geral%20ou%20diarreia.%20Em%20casos%20mais%20graves%2C%20os%20sintomas%20podem%20incluir%20aumento%20dos%20ov%26%23xE1%3Brios%2C%20ac%26%23xFA%3Bmulo%20de%20l%26%23xED%3Bquido%20no%20abdome%20e%2Fou%20t%26%23xF3%3Brax%20(que%20pode%20causar%20ganho%20de%20peso%20repentino%20devido%20ao%20ac%26%23xFA%3Bmulo%20de%20flu%26%23xED%3Bdo)%20e%20a%20ocorr%26%23xEA%3Bncia%20de%20co%26%23xE1%3Bgulos%20na%20circula%26%23xE7%3B%26%23xE3%3Bo.%20Contate%20o%20seu%20m%26%23xE9%3Bdico%20imediatamente%20se%20voc%26%23xEA%3B%20apresentar%20quaisquer%20desses%20sintomas%2C%20mesmo%20que%20eles%20ocorram%20alguns%20dias%20depois%20da%20administra%26%23xE7%3B%26%23xE3%3Bo%20da%20%26%23xFA%3Bltima%20inje%26%23xE7%3B%26%23xE3%3Bo.%3Cbr%3E%20Rea%26%23xE7%3B%26%23xE3%3Bo%20comum%20(ocorre%20entre%201%25%20e%2010%25%20dos%20pacientes%20que%20utilizam%20este%20medicamento)%3A%3Cbr%3E%20-Dor%20de%20cabe%26%23xE7%3Ba%3Cbr%3E%20-Rea%26%23xE7%3B%26%23xF5%3Bes%20no%20local%20da%20inje%26%23xE7%3B%26%23xE3%3Bo%20(tais%20como%20hematoma%2C%20dor%2C%20vermelhid%26%23xE3%3Bo%2C%20incha%26%23xE7%3Bo%20e%20coceira)%3Cbr%3E%20-S%26%23xED%3Bndrome%20de%20hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20(SHEO)%3Cbr%3E%20-Dor%20p%26%23xE9%3Blvica%3Cbr%3E%20-Dor%20estomacal%20e%2Fou%20incha%26%23xE7%3Bo%3Cbr%3E%20Rea%26%23xE7%3B%26%23xE3%3Bo%20incomum%20(ocorre%20entre%200%2C1%25%20e%201%25%20dos%20pacientes%20que%20utilizam%20este%20medicamento)%3A%3Cbr%3E%20-Queixas%20mam%26%23xE1%3Brias%20(incluindo%20sensibilidade)%3Cbr%3E%20-Diarreia%2C%20constipa%26%23xE7%3B%26%23xE3%3Bo%20ou%20desconforto%20estomacal%3Cbr%3E%20-Aumento%20do%20tamanho%20do%20%26%23xFA%3Btero%3Cbr%3E%20-Mal-estar%20geral%3Cbr%3E%20-Rea%26%23xE7%3B%26%23xF5%3Bes%20de%20hipersensibilidade%20(tais%20como%20erup%26%23xE7%3B%26%23xE3%3Bo%20cut%26%23xE2%3Bnea%2C%20vermelhid%26%23xE3%3Bo%2C%20urtic%26%23xE1%3Bria%20e%20coceira)%3Cbr%3E%20-Cistos%20ovarianos%20ou%20aumento%20do%20tamanho%20dos%20ov%26%23xE1%3Brios%3Cbr%3E%20-Tor%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20(tor%26%23xE7%3B%26%23xE3%3Bo%20nos%20ov%26%23xE1%3Brios)%3Cbr%3E%20-Sangramento%20vaginal%3Cbr%3E%20Rea%26%23xE7%3B%26%23xE3%3Bo%20rara%20(ocorre%20entre%200%2C01%25%20e%200%2C1%25%20dos%20pacientes%20que%20utilizam%20este%20medicamento)%3A%3Cbr%3E%20-Co%26%23xE1%3Bgulos%20sangu%26%23xED%3Bneos%20(isto%20tamb%26%23xE9%3Bm%20pode%20ocorrer%20na%20aus%26%23xEA%3Bncia%20de%20hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20indesejada%20dos%20ov%26%23xE1%3Brios.%20Veja%20tamb%26%23xE9%3Bm%20o%20item%20%26%23x93%3B4.%20O%20QUE%20DEVO%20SABER%20ANTES%20DE%20USAR%20ESTE%20MEDICAMENTO%3F%26%23x94%3B)%3Cbr%3E%20Gravidez%20fora%20do%20%26%23xFA%3Btero%20(gravidez%20ect%26%23xF3%3Bpica)%2C%20aborto%20e%20gesta%26%23xE7%3B%26%23xF5%3Bes%20m%26%23xFA%3Bltiplas%20t%26%23xEA%3Bm%20sido%20relatados.%20Essas%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20n%26%23xE3%3Bo%20s%26%23xE3%3Bo%20consideradas%20relacionadas%20com%20o%20uso%20de%20PUREGON%26%23xAE%3B%2C%20mas%20%26%23xE0%3B%20T%26%23xE9%3Bcnica%20de%20Reprodu%26%23xE7%3B%26%23xE3%3Bo%20Assistida%20(TRA)%20ou%20gravidez%20subsequente.%3Cbr%3E%20%3Cbr%3E%20Em%20homens%3A%3Cbr%3E%20Rea%26%23xE7%3B%26%23xE3%3Bo%20comum%20(ocorre%20entre%201%25%20e%2010%25%20dos%20pacientes%20que%20utilizam%20este%20medicamento)%3A%3Cbr%3E%20-Acne%3Cbr%3E%20-Endurecimento%20no%20local%20de%20inje%26%23xE7%3B%26%23xE3%3Bo%3Cbr%3E%20*Dor%20de%20cabe%26%23xE7%3Ba%3Cbr%3E%20-Erup%26%23xE7%3B%26%23xE3%3Bo%20cut%26%23xE2%3Bnea%3Cbr%3E%20-Desenvolvimento%20de%20mamas%3Cbr%3E%20-Cisto%20nos%20test%26%23xED%3Bculos%3Cbr%3E%20Se%20alguma%20das%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20se%20tornar%20grave%20ou%20se%20voc%26%23xEA%3B%20notar%20qualquer%20rea%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20mencionada%20nesta%20bula%2C%20informe%20ao%20seu%20m%26%23xE9%3Bdico%20ou%20farmac%26%23xEA%3Butico.%3Cbr%3E%20%3Cbr%3E%20Informe%20ao%20seu%20m%26%23xE9%3Bdico%2C%20cirurgi%26%23xE3%3Bo-dentista%20ou%20farmac%26%23xEA%3Butico%20o%20aparecimento%20de%20rea%26%23xE7%3B%26%23xF5%3Bes%20indesej%26%23xE1%3Bveis%20pelo%20uso%20do%20medicamento.%20Informe%20tamb%26%23xE9%3Bm%20%26%23xE0%3B%20empresa%20atrav%26%23xE9%3Bs%20do%20seu%20servi%26%23xE7%3Bo%20de%20atendimento.%3Cbr%3E%209.%20O%20QUE%20FAZER%20SE%20ALGU%26%23xC9%3BM%20USAR%20UMA%20QUANTIDADE%20MAIOR%20DO%20QUE%20A%20INDICADA%20DESTE%20MEDICAMENTO%3F%3Cbr%3E%20Informe%20ao%20seu%20m%26%23xE9%3Bdico%20imediatamente.%20Doses%20muito%20elevadas%20podem%20causar%20s%26%23xED%3Bndrome%20de%20hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20dos%20ov%26%23xE1%3Brios%20(SHEO).%20Os%20primeiros%20sintomas%20de%20hiperestimula%26%23xE7%3B%26%23xE3%3Bo%20ovariana%20podem%20ser%3A%20dor%20abdominal%2C%20mal-estar%20geral%20ou%20diarreia.%20Em%20casos%20mais%20graves%2C%20os%20sintomas%20podem%20incluir%20aumento%20dos%20ov%26%23xE1%3Brios%2C%20ac%26%23xFA%3Bmulo%20de%20l%26%23xED%3Bquido%20no%20abdome%20e%2Fou%20t%26%23xF3%3Brax%2C%20aumento%20de%20peso%20e%20ocorr%26%23xEA%3Bncia%20de%20co%26%23xE1%3Bgulos%20na%20circula%26%23xE7%3B%26%23xE3%3Bo%20(ver%20item%20%26%23x93%3B8.%20QUAIS%20OS%20MALES%20QUE%20ESTE%20MEDICAMENTO%20PODE%20ME%20CAUSAR%3F%26%23x94%3B).%3Cbr%3E%20%3Cbr%3E%20Em%20caso%20de%20uso%20de%20grande%20quantidade%20deste%20medicamento%2C%20procure%20rapidamente%20socorro%20m%26%23xE9%3Bdico%20e%20leve%20a%20embalagem%20ou%20bula%20do%20medicamento%2C%20se%20poss%26%23xED%3Bvel.%20Ligue%20para%200800%20722%206001%2C%20se%20voc%26%23xEA%3B%20precisar%20de%20mais%20orienta%26%23xE7%3B%26%23xF5%3Bes.%3C%2Fp%3E%0A%3Ch2%3EData%20da%20bula%3C%2Fh2%3E%0A%3Cp%3E07%2F08%2F2017%3C%2Fp%3E%0A%09%09%09%09%09%09
- Ame
- Sim
- ApresentarPrecoDePor
- Sim
- custom_label_0
- campanha
- MedicamentoControlado
- Não
- Termolabil
- True
- Cashback
- Não
- Antibiotico
- Não
- Generico
- Não
Tributos e contexto fiscal
Escolha o estado para ver os tributos deste produto:
Preferência salva neste navegador; confirme o destino da operação.
NCM, CEST e tributos são referências fiscais brasileiras e podem não se aplicar em outros países.
Selecione a UF nesta seção para consultar a estimativa IBPT.
IBS/CBS: o cClassTrib acima vem do enquadramento do NCM; percentuais dependem da operação, regime, data e destino.
Outros produtos em Medicamentos E Saúde
Códigos de barras próximos
Produtos com o mesmo início de código (7897572…), em geral do mesmo fabricante.
